https://trial.medpath.com/news/syncona-s-autolus-wins-fda-approval-for-aggressive-leukaemia-therapy-morningstar 2024-11-11T10:36:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syncona-s-autolus-wins-fda-approval-for-aggressive-leukaemia-therapy-morningstar 2024-11-11T10:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-11T10:34:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-11T10:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/data-fomo-may-undermine-clinical-trials-roi-phesi-warns-laboratory-news 2024-11-11T10:11:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-fomo-may-undermine-clinical-trials-roi-phesi-warns-laboratory-news 2024-11-11T10:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/tectonic-therapeutic-announces-positive-phase-1a-results-in-globenewswire 2024-11-11T10:01:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tectonic-therapeutic-announces-positive-phase-1a-results-in-globenewswire 2024-11-11T10:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/palleon-pharmaceuticals-reports-phase-i-ii-trial-results-of-e-602-for-solid-tumours 2024-11-11T09:56:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palleon-pharmaceuticals-reports-phase-i-ii-trial-results-of-e-602-for-solid-tumours 2024-11-11T09:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharmaceuticals-gets-usfda-nod-for-generic-hypertension-treatment-capsules 2024-11-11T09:42:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-gets-usfda-nod-for-generic-hypertension-treatment-capsules 2024-11-11T09:42:36+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-bags-fda-approval-for-leukaemia-cell-therapy-pharmaphorum 2024-11-11T09:35:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-bags-fda-approval-for-leukaemia-cell-therapy-pharmaphorum 2024-11-11T09:35:20+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharmaceuticals-gains-usfda-final-approval-for-diltiazem-hydrochloride-extended 2024-11-11T09:33:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-gains-usfda-final-approval-for-diltiazem-hydrochloride-extended 2024-11-11T09:33:59+00:00 weekly 0.7 https://trial.medpath.com/news/will-adlai-be-the-first-to-deliver-a-pi3k-inhibitor-for-head-and-neck-squamous-cell-carcinoma 2024-11-11T09:29:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/will-adlai-be-the-first-to-deliver-a-pi3k-inhibitor-for-head-and-neck-squamous-cell-carcinoma 2024-11-11T09:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-killing-virus-shows-promise-against-aggressive-brain-tumors 2024-11-11T09:19:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-killing-virus-shows-promise-against-aggressive-brain-tumors 2024-11-11T09:19:42+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-reports-business-pipeline-and-financial-update-for-q3-2024-pharmiweb-com 2024-11-11T09:18:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transgene-reports-business-pipeline-and-financial-update-for-q3-2024-pharmiweb-com 2024-11-11T09:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/research-suggests-no-need-for-yellow-fever-vaccine-booster-after-initial-dose 2024-11-11T09:15:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-suggests-no-need-for-yellow-fever-vaccine-booster-after-initial-dose 2024-11-11T09:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/shandong-xinhua-pharma-secures-key-drug-approval-tipranks-com 2024-11-11T09:14:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shandong-xinhua-pharma-secures-key-drug-approval-tipranks-com 2024-11-11T09:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-provides-business-update-with-third-quarter-2024-financial-results-biospace 2024-11-11T09:11:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-provides-business-update-with-third-quarter-2024-financial-results-biospace 2024-11-11T09:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/trump-s-healthcare-agenda-raises-concerns-rfk-jr-s-potential-role-and-aca-s-future-in-focus 2024-11-11T09:11:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trump-s-healthcare-agenda-raises-concerns-rfk-jr-s-potential-role-and-aca-s-future-in-focus 2024-11-11T09:11:05+00:00 weekly 0.7 https://trial.medpath.com/news/neurizon-therapeutics-receives-positive-opinion-on-orphan-medicinal-product-menafn 2024-11-11T09:11:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurizon-therapeutics-receives-positive-opinion-on-orphan-medicinal-product-menafn 2024-11-11T09:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-seeks-fda-approval-for-nsclc-treatment-sunvozertinib-pharmaceutical-technology 2024-11-11T09:01:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dizal-seeks-fda-approval-for-nsclc-treatment-sunvozertinib-pharmaceutical-technology 2024-11-11T09:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T09:01:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T09:01:39+00:00 weekly 0.7 https://trial.medpath.com/news/australia-and-uk-team-up-to-fund-clinical-trials-research-professional-news 2024-11-11T08:57:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/australia-and-uk-team-up-to-fund-clinical-trials-research-professional-news 2024-11-11T08:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/sweden-cereno-scientific-secures-financial-runway-into-2026-investors-in-healthcare 2024-11-11T08:55:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sweden-cereno-scientific-secures-financial-runway-into-2026-investors-in-healthcare 2024-11-11T08:55:20+00:00 weekly 0.7 https://trial.medpath.com/news/imugene-doses-first-patient-in-hard-to-treat-cancer-drug-trial-the-west-australian 2024-11-11T08:36:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imugene-doses-first-patient-in-hard-to-treat-cancer-drug-trial-the-west-australian 2024-11-11T08:36:44+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T08:36:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T08:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-s-autolus-gets-fda-approval-for-leukaemia-treatment-sharecast-com 2024-11-11T08:23:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syncona-s-autolus-gets-fda-approval-for-leukaemia-treatment-sharecast-com 2024-11-11T08:23:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-to-finally-ban-controversial-ingredient-in-popular-decongestants-sciencealert 2024-11-11T08:20:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-to-finally-ban-controversial-ingredient-in-popular-decongestants-sciencealert 2024-11-11T08:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/investment-surges-hurdles-and-emerging-innovations-in-neuroscience-yahoo 2024-11-11T08:10:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investment-surges-hurdles-and-emerging-innovations-in-neuroscience-yahoo 2024-11-11T08:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/neurizon-therapeutics-receives-positive-opinion-on-orphan-medicinal-product-pr-newswire 2024-11-11T08:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurizon-therapeutics-receives-positive-opinion-on-orphan-medicinal-product-pr-newswire 2024-11-11T08:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-receives-fda-approval-for-aucatzyl-in-adults-with-relapsed-refractory-b-all 2024-11-11T08:06:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-receives-fda-approval-for-aucatzyl-in-adults-with-relapsed-refractory-b-all 2024-11-11T08:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/enterobiotix-announces-positive-ph1b-clinical-results-of-ebx-102-in-liver-cirrhosis 2024-11-11T08:04:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enterobiotix-announces-positive-ph1b-clinical-results-of-ebx-102-in-liver-cirrhosis 2024-11-11T08:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-autolus-receives-fda-approval-for-aucatzyl-in-adults-with-relapsed-refractory-b-all 2024-11-11T07:55:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syncona-autolus-receives-fda-approval-for-aucatzyl-in-adults-with-relapsed-refractory-b-all 2024-11-11T07:55:36+00:00 weekly 0.7 https://trial.medpath.com/news/luye-pharma-gains-approval-for-innovative-antidepressant-trials-markets-insider 2024-11-11T07:55:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/luye-pharma-gains-approval-for-innovative-antidepressant-trials-markets-insider 2024-11-11T07:55:36+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:46:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-11T07:44:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-11T07:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/largest-t-cell-clinical-trial-in-solid-tumors-heralds-new-era-in-precision-immunotherapy 2024-11-11T07:41:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/largest-t-cell-clinical-trial-in-solid-tumors-heralds-new-era-in-precision-immunotherapy 2024-11-11T07:41:29+00:00 weekly 0.7 https://trial.medpath.com/news/gamma-delta-t-cells-emerge-as-promising-alternative-to-car-t-for-solid-tumors-and-autoimmune-diseases 2024-11-11T07:41:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gamma-delta-t-cells-emerge-as-promising-alternative-to-car-t-for-solid-tumors-and-autoimmune-diseases 2024-11-11T07:41:26+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharma-gets-usfda-approval-hypertension-drug-india-infoline 2024-11-11T07:38:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alembic-pharma-gets-usfda-approval-hypertension-drug-india-infoline 2024-11-11T07:38:49+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:20:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:20:56+00:00 weekly 0.7 https://trial.medpath.com/news/oncoinvent-announces-promising-interim-results-for-radspherin-r-as-a-potential-treatment 2024-11-11T07:20:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncoinvent-announces-promising-interim-results-for-radspherin-r-as-a-potential-treatment 2024-11-11T07:20:41+00:00 weekly 0.7 https://trial.medpath.com/news/angle-plc-announces-parsortix-enriched-ctc-ctdna-in-nsclc-patients-stock-titan 2024-11-11T07:17:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/angle-plc-announces-parsortix-enriched-ctc-ctdna-in-nsclc-patients-stock-titan 2024-11-11T07:17:37+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-s-autolus-gains-fda-approval-for-leukemia-therapy-tipranks-com 2024-11-11T07:14:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syncona-s-autolus-gains-fda-approval-for-leukemia-therapy-tipranks-com 2024-11-11T07:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/hemogenyx-pharmaceuticals-secures-funding-for-clinical-trials-tipranks-com 2024-11-11T07:13:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hemogenyx-pharmaceuticals-secures-funding-for-clinical-trials-tipranks-com 2024-11-11T07:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/cereno-scientific-secures-sek-250-million-in-debt-financing-marketscreener 2024-11-11T07:08:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cereno-scientific-secures-sek-250-million-in-debt-financing-marketscreener 2024-11-11T07:08:53+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-receives-us-fda-approval-company-announcement-investegate 2024-11-11T07:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-receives-us-fda-approval-company-announcement-investegate 2024-11-11T07:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/investment-surges-hurdles-and-emerging-innovations-in-neuroscience 2024-11-11T07:06:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investment-surges-hurdles-and-emerging-innovations-in-neuroscience 2024-11-11T07:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:02:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nordic-bioscience-receives-letter-of-support-from-the-fda-for-the-cpa9-hne-biomarker-in 2024-11-11T07:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/biomarker-testing-revolutionizes-treatment-approaches-in-diffuse-large-b-cell-lymphoma 2024-11-11T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarker-testing-revolutionizes-treatment-approaches-in-diffuse-large-b-cell-lymphoma 2024-11-11T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-announces-new-data-highlighting-potential-of-ciforadenant-biospace 2024-11-11T06:50:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-announces-new-data-highlighting-potential-of-ciforadenant-biospace 2024-11-11T06:50:03+00:00 weekly 0.7 https://trial.medpath.com/news/relief-therapeutics-eb-treatment-shows-78-wound-closure-rate-in-breakthrough-trial 2024-11-11T06:37:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relief-therapeutics-eb-treatment-shows-78-wound-closure-rate-in-breakthrough-trial 2024-11-11T06:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/curasight-announces-brain-cancer-as-first-indication-for-utreat-r-first-patient-to-be-dosed 2024-11-11T06:34:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curasight-announces-brain-cancer-as-first-indication-for-utreat-r-first-patient-to-be-dosed 2024-11-11T06:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/japan-recommends-approval-of-brukinza-balversa-citeline 2024-11-11T06:31:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/japan-recommends-approval-of-brukinza-balversa-citeline 2024-11-11T06:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-industry-adapts-to-evolving-challenges-ai-and-innovation-key-to-clinical-trial-success 2024-11-11T06:29:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-industry-adapts-to-evolving-challenges-ai-and-innovation-key-to-clinical-trial-success 2024-11-11T06:29:13+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-cardiovascular-and-renal-outcomes-of-liraglutide-versus-dulaglutide-in-asian 2024-11-11T06:28:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-cardiovascular-and-renal-outcomes-of-liraglutide-versus-dulaglutide-in-asian 2024-11-11T06:28:30+00:00 weekly 0.7 https://trial.medpath.com/news/major-t-cell-trial-in-solid-tumors-marks-new-era-mirage-news 2024-11-11T06:12:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/major-t-cell-trial-in-solid-tumors-marks-new-era-mirage-news 2024-11-11T06:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/alembic-pharma-gets-usfda-nod-for-hypertension-treatment-drug-cnbc-tv18 2024-11-11T05:38:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alembic-pharma-gets-usfda-nod-for-hypertension-treatment-drug-cnbc-tv18 2024-11-11T05:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-us-eu-approvals-for-darzalex-faspro-darzalex-as-pharmabiz-com 2024-11-11T05:31:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-us-eu-approvals-for-darzalex-faspro-darzalex-as-pharmabiz-com 2024-11-11T05:31:18+00:00 weekly 0.7 https://trial.medpath.com/news/5-huntington-s-therapies-to-watch-biospace 2024-11-11T05:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-huntington-s-therapies-to-watch-biospace 2024-11-11T05:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/after-decades-of-failure-first-disease-modifying-huntington-s-treatment-on-the-horizon 2024-11-11T05:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/after-decades-of-failure-first-disease-modifying-huntington-s-treatment-on-the-horizon 2024-11-11T05:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/genetic-study-reveals-strong-links-between-hidradenitis-suppurativa-and-cardiometabolic-diseases 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genetic-study-reveals-strong-links-between-hidradenitis-suppurativa-and-cardiometabolic-diseases 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-heart-valve-device-at-musc-offers-safer-treatment-for-tricuspid-regurgitation 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-heart-valve-device-at-musc-offers-safer-treatment-for-tricuspid-regurgitation 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pe-cgs-network-advances-patient-partnered-cancer-research-despite-implementation-challenges 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pe-cgs-network-advances-patient-partnered-cancer-research-despite-implementation-challenges 2024-11-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-and-nucleus-radiopharma-scale-up-manufacturing-for-cancer-treatment 2024-11-11T04:50:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarity-and-nucleus-radiopharma-scale-up-manufacturing-for-cancer-treatment 2024-11-11T04:50:53+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-tentative-u-s-fda-approval-for-raltegravir-tablets-express-pharma 2024-11-11T04:36:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupin-receives-tentative-u-s-fda-approval-for-raltegravir-tablets-express-pharma 2024-11-11T04:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-disease-clinical-research-in-7mm-focuses-on-disease-modifying-agents-says-globaldata 2024-11-11T04:32:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parkinson-s-disease-clinical-research-in-7mm-focuses-on-disease-modifying-agents-says-globaldata 2024-11-11T04:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/quick-listen-scrip-s-five-must-know-things-citeline 2024-11-11T04:32:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quick-listen-scrip-s-five-must-know-things-citeline 2024-11-11T04:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/hope-for-kenyans-as-kemri-recommends-new-hiv-prevention-drugs-tv47-digital 2024-11-11T04:24:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-for-kenyans-as-kemri-recommends-new-hiv-prevention-drugs-tv47-digital 2024-11-11T04:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/imugene-expands-car-t-cell-and-oncolytic-virotherapy-trials-in-australia-and-the-us 2024-11-11T04:23:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imugene-expands-car-t-cell-and-oncolytic-virotherapy-trials-in-australia-and-the-us 2024-11-11T04:23:42+00:00 weekly 0.7 https://trial.medpath.com/news/while-the-orphan-battles-wage-jazz-takes-a-loss-food-and-drugs-law-mondaq 2024-11-11T03:37:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/while-the-orphan-battles-wage-jazz-takes-a-loss-food-and-drugs-law-mondaq 2024-11-11T03:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-astrazeneca-s-enhertu-receives-2024-prix-galien-usa-award-for-best 2024-11-11T03:29:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daiichi-sankyo-astrazeneca-s-enhertu-receives-2024-prix-galien-usa-award-for-best 2024-11-11T03:29:34+00:00 weekly 0.7 https://trial.medpath.com/news/ema-accepts-marketing-authorization-application-for-alvotech-s-avt05-golimumab 2024-11-11T03:27:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-accepts-marketing-authorization-application-for-alvotech-s-avt05-golimumab 2024-11-11T03:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-presents-the-latest-clinical-data-of-anti-her2-bispecific-adc 2024-11-11T03:22:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alphamab-oncology-presents-the-latest-clinical-data-of-anti-her2-bispecific-adc 2024-11-11T03:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-therapeutics-announces-u-s-fda-acceptance-of-the-new-drug-application-nda-for-oxylanthanum-carbonate-olc-for-the-treatment-of-hyperphosphatemia-in-patients-with-chronic-kidney-disease-on-dialysis 2024-11-11T03:11:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unicycive-therapeutics-announces-u-s-fda-acceptance-of-the-new-drug-application-nda-for-oxylanthanum-carbonate-olc-for-the-treatment-of-hyperphosphatemia-in-patients-with-chronic-kidney-disease-on-dialysis 2024-11-11T03:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-advances-phase-3-trial-in-indonesia-markets-insider 2024-11-11T03:02:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-advances-phase-3-trial-in-indonesia-markets-insider 2024-11-11T03:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/late-breaking-abstract-alphamab-oncology-presented-the-latest-clinical-data-of-anti 2024-11-11T02:34:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/late-breaking-abstract-alphamab-oncology-presented-the-latest-clinical-data-of-anti 2024-11-11T02:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/nipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-living-with-moderate-to-severe-sjogrens-disease 2024-11-11T02:11:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-living-with-moderate-to-severe-sjogrens-disease 2024-11-11T02:11:39+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia 2024-11-11T02:11:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia 2024-11-11T02:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/sino-biopharm-s-garsorasib-gains-approval-in-china-markets-insider 2024-11-11T02:04:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sino-biopharm-s-garsorasib-gains-approval-in-china-markets-insider 2024-11-11T02:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-presents-positive-update-on-gtx-102-angelman-syndrome-program 2024-11-11T01:38:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-presents-positive-update-on-gtx-102-angelman-syndrome-program 2024-11-11T01:38:19+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-garners-ethics-approval-for-anti-infective-phase-3-clinical-trial-in-indonesia 2024-11-11T01:20:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-garners-ethics-approval-for-anti-infective-phase-3-clinical-trial-in-indonesia 2024-11-11T01:20:59+00:00 weekly 0.7 https://trial.medpath.com/news/australia-s-clarity-pharma-jumps-on-deal-with-us-co-tradingview 2024-11-11T01:20:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/australia-s-clarity-pharma-jumps-on-deal-with-us-co-tradingview 2024-11-11T01:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/could-everyday-plastics-be-impacting-your-fertility-newcastle-hmri 2024-11-11T00:29:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-everyday-plastics-be-impacting-your-fertility-newcastle-hmri 2024-11-11T00:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/ai-vs-humans-are-ai-chatbots-ready-for-real-mental-health-conversations-hmri 2024-11-11T00:29:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-vs-humans-are-ai-chatbots-ready-for-real-mental-health-conversations-hmri 2024-11-11T00:29:53+00:00 weekly 0.7 https://trial.medpath.com/news/ai-algorithm-achieves-80-precision-in-detecting-long-covid-through-electronic-health-records 2024-11-11T00:15:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-algorithm-achieves-80-precision-in-detecting-long-covid-through-electronic-health-records 2024-11-11T00:15:39+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-is-working-on-breast-cancer-vaccines-firstcoastnews-com 2024-11-11T00:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-is-working-on-breast-cancer-vaccines-firstcoastnews-com 2024-11-11T00:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-shows-effectiveness-of-nanoparticles-in-diagnosing-treating-plaque-in-arteries 2024-11-11T00:03:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-shows-effectiveness-of-nanoparticles-in-diagnosing-treating-plaque-in-arteries 2024-11-11T00:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-holding-promising-pipeline-and-market-potential-support-buy-rating 2024-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oculis-holding-promising-pipeline-and-market-potential-support-buy-rating 2024-11-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-biotech-stocks-on-the-move-in-october-claire-aitchison-livewire-markets 2024-11-10T23:54:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-biotech-stocks-on-the-move-in-october-claire-aitchison-livewire-markets 2024-11-10T23:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-advances-phase-3-trial-in-indonesia-tipranks-com 2024-11-10T23:48:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-advances-phase-3-trial-in-indonesia-tipranks-com 2024-11-10T23:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/naspghan-2024-pedfic-data-highlight-safety-of-odevixibat-in-pediatric-patients-with-pfic 2024-11-10T23:34:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/naspghan-2024-pedfic-data-highlight-safety-of-odevixibat-in-pediatric-patients-with-pfic 2024-11-10T23:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/participants-needed-for-clinical-trials-for-norovirus-nevada-appeal 2024-11-10T23:02:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/participants-needed-for-clinical-trials-for-norovirus-nevada-appeal 2024-11-10T23:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/digital-health-funding-roundup-aignostics-secures-34m-series-b-for-ai-powered-pathology-platform 2024-11-10T23:01:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-health-funding-roundup-aignostics-secures-34m-series-b-for-ai-powered-pathology-platform 2024-11-10T23:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-cure-for-lethal-skin-disease-achieved-in-landmark-study-wehi 2024-11-10T22:56:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-first-cure-for-lethal-skin-disease-achieved-in-landmark-study-wehi 2024-11-10T22:56:13+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-modelling-progressive-ms-in-the-lab-reveals-how-cholesterol-can-damage-nerves 2024-11-10T22:50:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-modelling-progressive-ms-in-the-lab-reveals-how-cholesterol-can-damage-nerves 2024-11-10T22:50:42+00:00 weekly 0.7 https://trial.medpath.com/news/roflumilast-cream-0-15-addresses-unmet-needs-of-adults-children-with-atopic-dermatitis 2024-11-10T21:42:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roflumilast-cream-0-15-addresses-unmet-needs-of-adults-children-with-atopic-dermatitis 2024-11-10T21:42:15+00:00 weekly 0.7 https://trial.medpath.com/news/cullinan-therapeutics-advances-novel-cd19-t-cell-engager-for-autoimmune-disease-treatment 2024-11-10T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cullinan-therapeutics-advances-novel-cd19-t-cell-engager-for-autoimmune-disease-treatment 2024-11-10T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-wants-to-pull-decongestant-found-in-many-cold-allergy-medicines-fox-26-houston 2024-11-10T19:26:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-wants-to-pull-decongestant-found-in-many-cold-allergy-medicines-fox-26-houston 2024-11-10T19:26:10+00:00 weekly 0.7 https://trial.medpath.com/news/intas-pharmaceuticals-gets-cdsco-panel-nod-to-study-r-hfsh-solution-for-injection 2024-11-10T18:43:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intas-pharmaceuticals-gets-cdsco-panel-nod-to-study-r-hfsh-solution-for-injection 2024-11-10T18:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/virus-therapy-gets-orphan-drug-designation-for-glioma-treatment-oncology-nursing-news 2024-11-10T18:06:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/virus-therapy-gets-orphan-drug-designation-for-glioma-treatment-oncology-nursing-news 2024-11-10T18:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/serial-killing-cell-therapy-from-autolus-lands-fda-approval-in-blood-cancer 2024-11-10T17:32:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/serial-killing-cell-therapy-from-autolus-lands-fda-approval-in-blood-cancer 2024-11-10T17:32:45+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-bids-to-add-smouldering-myeloma-to-darzalex-label-pharmaphorum 2024-11-10T17:28:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-bids-to-add-smouldering-myeloma-to-darzalex-label-pharmaphorum 2024-11-10T17:28:14+00:00 weekly 0.7 https://trial.medpath.com/news/antio-cel-shows-promising-results-in-relapsed-refractory-multiple-myeloma 2024-11-10T17:12:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antio-cel-shows-promising-results-in-relapsed-refractory-multiple-myeloma 2024-11-10T17:12:43+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-pill-passes-important-safety-trial-new-atlas 2024-11-10T16:43:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-pill-passes-important-safety-trial-new-atlas 2024-11-10T16:43:40+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-relmada-therapeutics-reports-q3-financials-focuses-on-rel-1017 2024-11-10T16:33:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-relmada-therapeutics-reports-q3-financials-focuses-on-rel-1017 2024-11-10T16:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/nktr-255-shows-promise-for-reversing-radiation-induced-lymphopenia-in-nsclc 2024-11-10T16:06:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nktr-255-shows-promise-for-reversing-radiation-induced-lymphopenia-in-nsclc 2024-11-10T16:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-assess-the-role-of-vitamin-k2-in-managing-nocturnal-leg-cramps 2024-11-10T15:06:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-assess-the-role-of-vitamin-k2-in-managing-nocturnal-leg-cramps 2024-11-10T15:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-globenewswire 2024-11-10T14:37:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-presents-late-breaking-abstract-featuring-data-globenewswire 2024-11-10T14:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-trial-raises-concerns-for-accelerating-cognitive-decline-new-atlas 2024-11-10T14:26:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-trial-raises-concerns-for-accelerating-cognitive-decline-new-atlas 2024-11-10T14:26:11+00:00 weekly 0.7 https://trial.medpath.com/news/harbinger-health-to-speed-up-clinical-cancer-test-validation-european-biotechnology 2024-11-10T14:23:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harbinger-health-to-speed-up-clinical-cancer-test-validation-european-biotechnology 2024-11-10T14:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-s-promising-trial-results-bolster-prospects-markets-insider 2024-11-10T13:56:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alphamab-oncology-s-promising-trial-results-bolster-prospects-markets-insider 2024-11-10T13:56:34+00:00 weekly 0.7 https://trial.medpath.com/news/establishment-and-characterization-of-mouse-metabolic-dysfunction-associated-nature 2024-11-10T12:47:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/establishment-and-characterization-of-mouse-metabolic-dysfunction-associated-nature 2024-11-10T12:47:02+00:00 weekly 0.7 https://trial.medpath.com/news/implementing-palliative-care-in-hepatocellular-carcinoma-ambulatory-clinics-study-protocol 2024-11-10T12:45:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/implementing-palliative-care-in-hepatocellular-carcinoma-ambulatory-clinics-study-protocol 2024-11-10T12:45:04+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-discovery-links-manuka-honey-to-breast-cancer-treatment-evrim-agaci 2024-11-10T12:42:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-discovery-links-manuka-honey-to-breast-cancer-treatment-evrim-agaci 2024-11-10T12:42:49+00:00 weekly 0.7 https://trial.medpath.com/news/elan-investor-update-did-elanco-animal-health-mislead-globenewswire 2024-11-10T12:17:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elan-investor-update-did-elanco-animal-health-mislead-globenewswire 2024-11-10T12:17:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-self-collection-hpv-tests-as-an-alternative-to-pap-smears-columbia-missourian 2024-11-10T12:07:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-self-collection-hpv-tests-as-an-alternative-to-pap-smears-columbia-missourian 2024-11-10T12:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-a-review-of-last-month-s-fda-prominent-actions-and-key-data 2024-11-10T12:05:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-targeted-pulse-a-review-of-last-month-s-fda-prominent-actions-and-key-data 2024-11-10T12:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/what-prevents-fda-approval-of-sublingual-immunotherapy-new-york-city-ny-patch 2024-11-10T11:01:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-prevents-fda-approval-of-sublingual-immunotherapy-new-york-city-ny-patch 2024-11-10T11:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/jnj-seeks-approval-from-usfda-ema-for-darzalex-faspro-as-subcutaneous 2024-11-10T10:54:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jnj-seeks-approval-from-usfda-ema-for-darzalex-faspro-as-subcutaneous 2024-11-10T10:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/hyperbaric-oxygen-therapy-for-combat-associated-ptsd-psychiatrist-com 2024-11-10T10:12:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hyperbaric-oxygen-therapy-for-combat-associated-ptsd-psychiatrist-com 2024-11-10T10:12:21+00:00 weekly 0.7 https://trial.medpath.com/news/water-bead-injuries-in-children-show-alarming-rise-national-study-reports-9-requiring-escalated-care 2024-11-10T09:48:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/water-bead-injuries-in-children-show-alarming-rise-national-study-reports-9-requiring-escalated-care 2024-11-10T09:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-s-rp1-shows-33-6-response-rate-in-melanoma-trial-marks-breakthrough-stock-titan 2024-11-10T09:43:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-s-rp1-shows-33-6-response-rate-in-melanoma-trial-marks-breakthrough-stock-titan 2024-11-10T09:43:02+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-delcath-systems-q3-2024-results-show-robust-growth-investing-com 2024-11-10T09:24:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-delcath-systems-q3-2024-results-show-robust-growth-investing-com 2024-11-10T09:24:07+00:00 weekly 0.7 https://trial.medpath.com/news/after-germany-france-and-italy-suspend-the-astrazeneca-vaccine-of-covid-19-telegrafi 2024-11-10T07:47:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/after-germany-france-and-italy-suspend-the-astrazeneca-vaccine-of-covid-19-telegrafi 2024-11-10T07:47:53+00:00 weekly 0.7 https://trial.medpath.com/news/erythropoietin-exposure-in-neonates-with-hypoxic-ischemic-encephalopathy-in-the-heal-trial 2024-11-10T07:23:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/erythropoietin-exposure-in-neonates-with-hypoxic-ischemic-encephalopathy-in-the-heal-trial 2024-11-10T07:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/early-smoking-cessation-treatment-after-cancer-diagnosis-significantly-boosts-survival-rates 2024-11-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-smoking-cessation-treatment-after-cancer-diagnosis-significantly-boosts-survival-rates 2024-11-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-announces-new-data-highlighting-potential-of-ciforadenant-to 2024-11-10T06:56:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-announces-new-data-highlighting-potential-of-ciforadenant-to 2024-11-10T06:56:54+00:00 weekly 0.7 https://trial.medpath.com/news/fate-therapeutics-highlights-cancer-selective-her2-targeting-profile-of-ft825-ono 2024-11-10T06:47:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fate-therapeutics-highlights-cancer-selective-her2-targeting-profile-of-ft825-ono 2024-11-10T06:47:10+00:00 weekly 0.7 https://trial.medpath.com/news/marengo-presents-promising-first-in-human-safety-tolerability-and-clinical-activity-data-for 2024-11-10T06:00:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marengo-presents-promising-first-in-human-safety-tolerability-and-clinical-activity-data-for 2024-11-10T06:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-ocugen-outlines-progress-in-ophthalmology-trials-financials-investing-com 2024-11-10T05:33:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-ocugen-outlines-progress-in-ophthalmology-trials-financials-investing-com 2024-11-10T05:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-strong-link-between-undiagnosed-asthma-and-insomnia-risk 2024-11-10T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-strong-link-between-undiagnosed-asthma-and-insomnia-risk 2024-11-10T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncoresponse-announces-phase-1-results-of-the-clinical-trial-of-or502-anti-lilrb2 2024-11-10T04:37:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncoresponse-announces-phase-1-results-of-the-clinical-trial-of-or502-anti-lilrb2 2024-11-10T04:37:16+00:00 weekly 0.7 https://trial.medpath.com/news/therapeutic-potential-of-neuroimmune-modulation-in-treatment-paradigm-of-relapsing 2024-11-10T04:07:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/therapeutic-potential-of-neuroimmune-modulation-in-treatment-paradigm-of-relapsing 2024-11-10T04:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/hong-kong-approves-celebrity-weight-loss-drug-but-experts-say-it-s-not-just-to-look-good 2024-11-10T04:06:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hong-kong-approves-celebrity-weight-loss-drug-but-experts-say-it-s-not-just-to-look-good 2024-11-10T04:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/ama-debates-physician-compensation-for-prior-authorization-work-at-interim-meeting 2024-11-10T03:38:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ama-debates-physician-compensation-for-prior-authorization-work-at-interim-meeting 2024-11-10T03:38:20+00:00 weekly 0.7 https://trial.medpath.com/news/bladder-cancer-treatment-paradigm-shifts-with-enfortumab-vedotin-pembrolizumab-combination-expert-highlights-at-sylvester-oncology-update 2024-11-10T03:00:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bladder-cancer-treatment-paradigm-shifts-with-enfortumab-vedotin-pembrolizumab-combination-expert-highlights-at-sylvester-oncology-update 2024-11-10T03:00:48+00:00 weekly 0.7 https://trial.medpath.com/news/day-3-recap-elevate-derm-west-2024-dermatology-times 2024-11-10T02:53:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/day-3-recap-elevate-derm-west-2024-dermatology-times 2024-11-10T02:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-10T02:33:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-10T02:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/lower-pharmacy-costs-give-ruxolitinib-edge-for-patients-with-mf-and-anemia 2024-11-10T01:32:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lower-pharmacy-costs-give-ruxolitinib-edge-for-patients-with-mf-and-anemia 2024-11-10T01:32:04+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-research-highlights-sitc-2024-special-edition 2024-11-10T01:12:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-research-highlights-sitc-2024-special-edition 2024-11-10T01:12:21+00:00 weekly 0.7 https://trial.medpath.com/news/another-signal-of-concern-with-abacavir-and-cardiovascular-risk-catie-ca 2024-11-10T00:53:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/another-signal-of-concern-with-abacavir-and-cardiovascular-risk-catie-ca 2024-11-10T00:53:50+00:00 weekly 0.7 https://trial.medpath.com/news/lauren-collen-md-advanced-combination-therapy-may-be-effective-option-for-pediatric 2024-11-10T00:39:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lauren-collen-md-advanced-combination-therapy-may-be-effective-option-for-pediatric 2024-11-10T00:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-10T00:21:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-10T00:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/palvella-therapeutics-begins-phase-3-trial-for-microcystic-lymphatic-malformations-treatment 2024-11-10T00:12:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palvella-therapeutics-begins-phase-3-trial-for-microcystic-lymphatic-malformations-treatment 2024-11-10T00:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-corneal-transplants-using-human-ips-cells-restores-vision-gurufocus 2024-11-10T00:10:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-corneal-transplants-using-human-ips-cells-restores-vision-gurufocus 2024-11-10T00:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/cab-gel-shows-promising-results-for-hispanic-patients-with-acne-dermatology-times 2024-11-10T00:06:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cab-gel-shows-promising-results-for-hispanic-patients-with-acne-dermatology-times 2024-11-10T00:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/tarlatamab-dlle-for-previously-treated-extensive-stage-sclc 2024-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tarlatamab-dlle-for-previously-treated-extensive-stage-sclc 2024-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/icecure-medical-s-prosense-system-gains-favorable-fda-panel-recommendation-and 2024-11-09T23:40:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icecure-medical-s-prosense-system-gains-favorable-fda-panel-recommendation-and 2024-11-09T23:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/post-hoc-analysis-reveals-potential-serum-glycoproteomic-biomarkers-for-nivolumab-onclive 2024-11-09T23:04:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/post-hoc-analysis-reveals-potential-serum-glycoproteomic-biomarkers-for-nivolumab-onclive 2024-11-09T23:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-for-kidney-cancer-builds-on-efficacy-record-medpage-today 2024-11-09T22:57:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-for-kidney-cancer-builds-on-efficacy-record-medpage-today 2024-11-09T22:57:19+00:00 weekly 0.7 https://trial.medpath.com/news/as-ai-transforms-drug-development-fda-is-scrambling-to-figure-out-guardrails-law-com 2024-11-09T22:30:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/as-ai-transforms-drug-development-fda-is-scrambling-to-figure-out-guardrails-law-com 2024-11-09T22:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/a2-bio-highlights-progress-of-tmodtm-car-t-cell-clinical-programs-during-2024-annual 2024-11-09T22:28:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a2-bio-highlights-progress-of-tmodtm-car-t-cell-clinical-programs-during-2024-annual 2024-11-09T22:28:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-proposes-ban-on-over-the-counter-decongestant-nevada-globe 2024-11-09T22:27:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-proposes-ban-on-over-the-counter-decongestant-nevada-globe 2024-11-09T22:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m17d1-in-advanced 2024-11-09T22:27:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m17d1-in-advanced 2024-11-09T22:27:11+00:00 weekly 0.7 https://trial.medpath.com/news/a2-bio-highlights-progress-of-tmodtm-car-t-cell-clinical-programs-during-2024-annual 2024-11-09T22:19:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a2-bio-highlights-progress-of-tmodtm-car-t-cell-clinical-programs-during-2024-annual 2024-11-09T22:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/benralizumab-effectiveness-in-patients-with-severe-eosinophilic-asthm-jaa-dove-medical-press 2024-11-09T22:16:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benralizumab-effectiveness-in-patients-with-severe-eosinophilic-asthm-jaa-dove-medical-press 2024-11-09T22:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/novel-bladder-cancer-treatment-gains-mhra-approval-in-the-uk-news-medical 2024-11-09T22:00:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-bladder-cancer-treatment-gains-mhra-approval-in-the-uk-news-medical 2024-11-09T22:00:03+00:00 weekly 0.7 https://trial.medpath.com/news/fate-therapeutics-highlights-cancer-selective-globenewswire 2024-11-09T21:37:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fate-therapeutics-highlights-cancer-selective-globenewswire 2024-11-09T21:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-biotechnologies-get-expanded-medicare-coverage-of-clonoseq-for-pharmabiz-com 2024-11-09T21:29:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptive-biotechnologies-get-expanded-medicare-coverage-of-clonoseq-for-pharmabiz-com 2024-11-09T21:29:41+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-in-ophthalmology-week-of-november-4-2024 2024-11-09T21:16:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-week-in-ophthalmology-week-of-november-4-2024 2024-11-09T21:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-allogene-therapeutics-reports-on-car-t-therapy-progress-by-investing-com 2024-11-09T21:12:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-allogene-therapeutics-reports-on-car-t-therapy-progress-by-investing-com 2024-11-09T21:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/details-surrounding-phase-3-study-of-ion582-in-angelman-syndrome-announced 2024-11-09T20:27:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/details-surrounding-phase-3-study-of-ion582-in-angelman-syndrome-announced 2024-11-09T20:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/delta-2-trial-shows-delgocitinib-cream-safe-with-minimal-systemic-absorption-for-chronic 2024-11-09T20:11:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delta-2-trial-shows-delgocitinib-cream-safe-with-minimal-systemic-absorption-for-chronic 2024-11-09T20:11:40+00:00 weekly 0.7 https://trial.medpath.com/news/japanese-researchers-discover-drug-that-regenerates-teeth-in-just-6-years-union-rayo 2024-11-09T19:54:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/japanese-researchers-discover-drug-that-regenerates-teeth-in-just-6-years-union-rayo 2024-11-09T19:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/askbio-receives-us-fda-rare-paediatric-disease-orphan-drug-designations-for-ab-1003-to 2024-11-09T19:29:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/askbio-receives-us-fda-rare-paediatric-disease-orphan-drug-designations-for-ab-1003-to 2024-11-09T19:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/fixed-duration-1l-cll-treatment-reduces-long-term-costs-in-the-real-world 2024-11-09T19:18:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fixed-duration-1l-cll-treatment-reduces-long-term-costs-in-the-real-world 2024-11-09T19:18:28+00:00 weekly 0.7 https://trial.medpath.com/news/aprea-therapeutics-reports-q3-financials-and-advances-in-clinical-trials-mychesco 2024-11-09T19:17:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aprea-therapeutics-reports-q3-financials-and-advances-in-clinical-trials-mychesco 2024-11-09T19:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/vistagen-therapeutics-promising-clinical-progress-and-strong-financial-position-justify-buy-rating 2024-11-09T19:01:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vistagen-therapeutics-promising-clinical-progress-and-strong-financial-position-justify-buy-rating 2024-11-09T19:01:39+00:00 weekly 0.7 https://trial.medpath.com/news/good-news-this-week-november-9-2024-dogs-ferrets-woodpeckers 2024-11-09T19:01:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/good-news-this-week-november-9-2024-dogs-ferrets-woodpeckers 2024-11-09T19:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-announces-new-data-highlighting-globenewswire 2024-11-09T18:51:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-announces-new-data-highlighting-globenewswire 2024-11-09T18:51:28+00:00 weekly 0.7 https://trial.medpath.com/news/team-at-mayo-clinic-in-arizona-completes-first-larynx-transplant 2024-11-09T18:50:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/team-at-mayo-clinic-in-arizona-completes-first-larynx-transplant 2024-11-09T18:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-09T18:49:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-09T18:49:19+00:00 weekly 0.7 https://trial.medpath.com/news/marengo-presents-promising-first-in-human-safety-tolerability-and-clinical-activity-data-for 2024-11-09T18:44:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marengo-presents-promising-first-in-human-safety-tolerability-and-clinical-activity-data-for 2024-11-09T18:44:22+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-pharmaceutical-inc-presents-positive-update-on-gtx-102-angelman-syndrome 2024-11-09T18:35:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-pharmaceutical-inc-presents-positive-update-on-gtx-102-angelman-syndrome 2024-11-09T18:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-to-present-long-term-efficacy-and-safety-data-from-phase-3-defi-trial-of-ogsiveo 2024-11-09T18:30:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springworks-to-present-long-term-efficacy-and-safety-data-from-phase-3-defi-trial-of-ogsiveo 2024-11-09T18:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of-rp1 2024-11-09T18:17:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of-rp1 2024-11-09T18:17:42+00:00 weekly 0.7 https://trial.medpath.com/news/linaclotide-effective-for-functional-constipation-in-children-with-neurodevelopmental-disorders 2024-11-09T18:07:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/linaclotide-effective-for-functional-constipation-in-children-with-neurodevelopmental-disorders 2024-11-09T18:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-late-breaking-abstract-featuring-data-globenewswire 2024-11-09T18:06:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-presents-late-breaking-abstract-featuring-data-globenewswire 2024-11-09T18:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/views-everyone-must-do-more-to-take-care-of-veterans-shaw-local 2024-11-09T18:03:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/views-everyone-must-do-more-to-take-care-of-veterans-shaw-local 2024-11-09T18:03:28+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-rimegepant-medical-dialogues 2024-11-09T17:07:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-rimegepant-medical-dialogues 2024-11-09T17:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/hold-recommendation-for-vir-biotechnology-amid-cautious-optimism-on-infectious-disease 2024-11-09T17:04:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hold-recommendation-for-vir-biotechnology-amid-cautious-optimism-on-infectious-disease 2024-11-09T17:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/a1c-drink-inc-announces-start-of-clinical-trials-in-early-2025-targeting-a-breakthrough-in 2024-11-09T16:41:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a1c-drink-inc-announces-start-of-clinical-trials-in-early-2025-targeting-a-breakthrough-in 2024-11-09T16:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/ga-therapies-coming-down-the-pike-modern-retina 2024-11-09T16:33:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ga-therapies-coming-down-the-pike-modern-retina 2024-11-09T16:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytic-immunotherapy-with-nivolumab-in-muscle-invasive-bladder-cancer-a-phase-1b-trial 2024-11-09T16:29:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncolytic-immunotherapy-with-nivolumab-in-muscle-invasive-bladder-cancer-a-phase-1b-trial 2024-11-09T16:29:48+00:00 weekly 0.7 https://trial.medpath.com/news/study-documents-detrimental-effects-of-drug-shortages-in-this-case-etoposide 2024-11-09T16:16:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-documents-detrimental-effects-of-drug-shortages-in-this-case-etoposide 2024-11-09T16:16:33+00:00 weekly 0.7 https://trial.medpath.com/news/rhythm-pharmaceuticals-hr-chief-pamela-cramer-sells-585940-in-stock-investing-com 2024-11-09T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-hr-chief-pamela-cramer-sells-585940-in-stock-investing-com 2024-11-09T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-arcturus-therapeutics-reported-a-net-loss-of-6-9-million-investing-com 2024-11-09T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-arcturus-therapeutics-reported-a-net-loss-of-6-9-million-investing-com 2024-11-09T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/next-steps-for-cilta-cel-and-cartitude-4-in-multiple-myeloma-targeted-oncology 2024-11-09T16:05:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-steps-for-cilta-cel-and-cartitude-4-in-multiple-myeloma-targeted-oncology 2024-11-09T16:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-presents-positive-update-on-gtx-102-angelman-syndrome-program-at-fast-s 2024-11-09T15:54:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-presents-positive-update-on-gtx-102-angelman-syndrome-program-at-fast-s 2024-11-09T15:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-presents-positive-update-on-gtx-102-angelman-globenewswire 2024-11-09T15:31:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-presents-positive-update-on-gtx-102-angelman-globenewswire 2024-11-09T15:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/promising-os-at-5-years-with-chemo-free-combo-in-urothelial-cancer-medpage-today 2024-11-09T15:31:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-os-at-5-years-with-chemo-free-combo-in-urothelial-cancer-medpage-today 2024-11-09T15:31:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mi-cancer-seek-as-companion-diagnostic-for-adult-and-pediatric-patients 2024-11-09T15:07:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-mi-cancer-seek-as-companion-diagnostic-for-adult-and-pediatric-patients 2024-11-09T15:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/caligan-takes-a-stake-in-verona-pharma-sees-opportunity-to-generate-more-value-cnbc 2024-11-09T14:54:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caligan-takes-a-stake-in-verona-pharma-sees-opportunity-to-generate-more-value-cnbc 2024-11-09T14:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/indapta-therapeutics-presents-clinical-and-preclinical-data-of-allogenic-natural-killer-cell 2024-11-09T14:51:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indapta-therapeutics-presents-clinical-and-preclinical-data-of-allogenic-natural-killer-cell 2024-11-09T14:51:52+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-09T14:47:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-09T14:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/urgent-ozempic-and-wegovy-warning-as-10-deaths-linked-to-weight-loss-jabs-the-mirror 2024-11-09T14:45:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urgent-ozempic-and-wegovy-warning-as-10-deaths-linked-to-weight-loss-jabs-the-mirror 2024-11-09T14:45:15+00:00 weekly 0.7 https://trial.medpath.com/news/red-flag-symptoms-of-condition-affecting-69000-women-as-hopes-grow-of-cure-surrey-live 2024-11-09T14:23:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/red-flag-symptoms-of-condition-affecting-69000-women-as-hopes-grow-of-cure-surrey-live 2024-11-09T14:23:21+00:00 weekly 0.7 https://trial.medpath.com/news/global-study-reveals-stark-disparities-in-biologic-access-for-atopic-dermatitis-treatment-across-50-countries 2024-11-09T14:00:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-study-reveals-stark-disparities-in-biologic-access-for-atopic-dermatitis-treatment-across-50-countries 2024-11-09T14:00:16+00:00 weekly 0.7 https://trial.medpath.com/news/allovir-sees-a-new-direction-with-kalaris-merger-bioworld 2024-11-09T13:51:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allovir-sees-a-new-direction-with-kalaris-merger-bioworld 2024-11-09T13:51:44+00:00 weekly 0.7 https://trial.medpath.com/news/new-car-t-cell-therapy-approved-for-leukemia-medpage-today 2024-11-09T13:39:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-car-t-cell-therapy-approved-for-leukemia-medpage-today 2024-11-09T13:39:29+00:00 weekly 0.7 https://trial.medpath.com/news/health-canada-approval-for-moderna-s-rsv-vaccine-biotechnology-the-pharmaletter 2024-11-09T13:07:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-canada-approval-for-moderna-s-rsv-vaccine-biotechnology-the-pharmaletter 2024-11-09T13:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/the-oncfive-top-oncology-articles-for-the-week-of-11-3-onclive 2024-11-09T13:05:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-oncfive-top-oncology-articles-for-the-week-of-11-3-onclive 2024-11-09T13:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-places-hold-on-rap-219-cappricorn-1-study-to-assess-mivelsiran-in-caa-fda 2024-11-09T12:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-places-hold-on-rap-219-cappricorn-1-study-to-assess-mivelsiran-in-caa-fda 2024-11-09T12:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-seeks-us-fda-approval-for-sunvozertinib-to-treat-relapsed-or-refractory-nsclc-with 2024-11-09T11:30:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dizal-seeks-us-fda-approval-for-sunvozertinib-to-treat-relapsed-or-refractory-nsclc-with 2024-11-09T11:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/subgroup-analyses-give-weight-for-next-level-trial-of-gv1001-in-progressive-supranuclear-palsy 2024-11-09T11:13:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subgroup-analyses-give-weight-for-next-level-trial-of-gv1001-in-progressive-supranuclear-palsy 2024-11-09T11:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/exclusive-clinical-trials-to-assess-health-benefits-of-ricky-kej-s-grammy-nominated 2024-11-09T11:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exclusive-clinical-trials-to-assess-health-benefits-of-ricky-kej-s-grammy-nominated 2024-11-09T11:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/rising-revenue-strategic-pipeline-advances-propel-biotech-growth-trajectory 2024-11-09T10:58:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rising-revenue-strategic-pipeline-advances-propel-biotech-growth-trajectory 2024-11-09T10:58:14+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-tentative-approval-from-usfda-for-raltegravir-tablets-indian-pharma-post 2024-11-09T10:53:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupin-receives-tentative-approval-from-usfda-for-raltegravir-tablets-indian-pharma-post 2024-11-09T10:53:38+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-review-tapinarof-cream-1-timeline-menacwy-vaccination-program-and-more 2024-11-09T10:17:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekly-review-tapinarof-cream-1-timeline-menacwy-vaccination-program-and-more 2024-11-09T10:17:19+00:00 weekly 0.7 https://trial.medpath.com/news/2-new-studies-highlight-issues-with-treatment-of-anaphylaxis-hcplive 2024-11-09T10:09:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2-new-studies-highlight-issues-with-treatment-of-anaphylaxis-hcplive 2024-11-09T10:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/cleveland-clinic-presents-new-findings-on-triple-negative-breast-cancer-vaccine 2024-11-09T09:47:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cleveland-clinic-presents-new-findings-on-triple-negative-breast-cancer-vaccine 2024-11-09T09:47:53+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-puma-biotechnology-reports-robust-q3-growth-investing-com 2024-11-09T09:10:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-puma-biotechnology-reports-robust-q3-growth-investing-com 2024-11-09T09:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/entera-bio-reports-q3-2024-financial-results-and-provides-business-updates 2024-11-09T09:07:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/entera-bio-reports-q3-2024-financial-results-and-provides-business-updates 2024-11-09T09:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/aptose-reports-results-for-the-third-quarter-2024-globenewswire 2024-11-09T09:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aptose-reports-results-for-the-third-quarter-2024-globenewswire 2024-11-09T09:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-drug-shortages-hit-decade-high-with-323-active-cases-ashp-reports 2024-11-09T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-drug-shortages-hit-decade-high-with-323-active-cases-ashp-reports 2024-11-09T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-providers-strongly-support-lowering-pneumococcal-vaccine-age-recommendation-to-50-years 2024-11-09T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healthcare-providers-strongly-support-lowering-pneumococcal-vaccine-age-recommendation-to-50-years 2024-11-09T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/philips-enrolls-first-patient-in-clinical-trial-for-integrated-single-device-to-treat-pad-daic 2024-11-09T08:56:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/philips-enrolls-first-patient-in-clinical-trial-for-integrated-single-device-to-treat-pad-daic 2024-11-09T08:56:47+00:00 weekly 0.7 https://trial.medpath.com/news/at-fortune-global-forum-2024-alex-zhavoronko-eurekalert 2024-11-09T08:50:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/at-fortune-global-forum-2024-alex-zhavoronko-eurekalert 2024-11-09T08:50:49+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-the-current-use-and-future-of-alternatives-to-traditional-informed-consent-in-acute 2024-11-09T08:37:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exploring-the-current-use-and-future-of-alternatives-to-traditional-informed-consent-in-acute 2024-11-09T08:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/thio-plus-cemiplimab-displays-efficacy-in-checkpoint-inhibitor-resistant-nsclc 2024-11-09T08:33:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thio-plus-cemiplimab-displays-efficacy-in-checkpoint-inhibitor-resistant-nsclc 2024-11-09T08:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-nec-to-present-new-data-confirming-clinical-proof-of-principle-for-neoantigen 2024-11-09T08:29:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transgene-nec-to-present-new-data-confirming-clinical-proof-of-principle-for-neoantigen 2024-11-09T08:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-evaluate-the-safety-and-efficacy-of-brivudine-as-oral-shingles-treatment 2024-11-09T08:25:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-evaluate-the-safety-and-efficacy-of-brivudine-as-oral-shingles-treatment 2024-11-09T08:25:37+00:00 weekly 0.7 https://trial.medpath.com/news/cd47-levels-are-prognostic-of-response-to-magrolimab-plus-docetaxel-in-metastatic-nsclc 2024-11-09T08:19:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cd47-levels-are-prognostic-of-response-to-magrolimab-plus-docetaxel-in-metastatic-nsclc 2024-11-09T08:19:30+00:00 weekly 0.7 https://trial.medpath.com/news/combining-lutetium-psma-with-hormonal-therapy-enhances-prostate-cancer-treatment 2024-11-09T08:18:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combining-lutetium-psma-with-hormonal-therapy-enhances-prostate-cancer-treatment 2024-11-09T08:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-vibostolimab-pembrolizumab-plus-chemo-meets-futility-threshold-in-es-sclc 2024-11-09T08:13:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontline-vibostolimab-pembrolizumab-plus-chemo-meets-futility-threshold-in-es-sclc 2024-11-09T08:13:42+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-reports-q3-2024-results-amid-fda-review-markets-insider 2024-11-09T08:12:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-reports-q3-2024-results-amid-fda-review-markets-insider 2024-11-09T08:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-november-8-2024 2024-11-09T08:04:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-november-8-2024 2024-11-09T08:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/pd-l1-kim-1-expression-are-predictive-of-outcomes-with-adjuvant-nivolumab-alone-plus 2024-11-09T07:59:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pd-l1-kim-1-expression-are-predictive-of-outcomes-with-adjuvant-nivolumab-alone-plus 2024-11-09T07:59:09+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-wins-fda-approval-of-aucatzyl-for-acute-lymphoblastic-leukemia-seeking-alpha 2024-11-09T07:32:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-wins-fda-approval-of-aucatzyl-for-acute-lymphoblastic-leukemia-seeking-alpha 2024-11-09T07:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-balversa-gains-mhra-marketing-authorization-as-monotherapy-for-bladder-cancer 2024-11-09T06:31:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-balversa-gains-mhra-marketing-authorization-as-monotherapy-for-bladder-cancer 2024-11-09T06:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-here-s-why 2024-11-09T06:18:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-here-s-why 2024-11-09T06:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-renews-reduced-risk-authorization-for-eight-swedish-match-products 2024-11-09T06:13:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-renews-reduced-risk-authorization-for-eight-swedish-match-products 2024-11-09T06:13:39+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-evaluation-of-a-novel-hemostatic-gelatin-matrix-for-intraoperative-hemostasis 2024-11-09T06:01:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-evaluation-of-a-novel-hemostatic-gelatin-matrix-for-intraoperative-hemostasis 2024-11-09T06:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/trontinemab-data-strengthen-hope-for-brain-shuttles-alzforum 2024-11-09T06:00:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trontinemab-data-strengthen-hope-for-brain-shuttles-alzforum 2024-11-09T06:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-bla-for-shanghai-henlius-biotech-s-and-organon-s-hlx14-a-denosumab-biosimilar 2024-11-09T05:58:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-bla-for-shanghai-henlius-biotech-s-and-organon-s-hlx14-a-denosumab-biosimilar 2024-11-09T05:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-resumes-study-of-pulse-field-ablation-as-first-line-afib-therapy 2024-11-09T05:35:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-resumes-study-of-pulse-field-ablation-as-first-line-afib-therapy 2024-11-09T05:35:15+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-positioned-for-growth-with-promising-trial-developments-and-strong-financials 2024-11-09T05:31:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kura-oncology-positioned-for-growth-with-promising-trial-developments-and-strong-financials 2024-11-09T05:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-webwire 2024-11-09T05:14:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-webwire 2024-11-09T05:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-offers-promise-for-terrible-terrible-brain-cancer-in-young-people 2024-11-09T05:03:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatment-offers-promise-for-terrible-terrible-brain-cancer-in-young-people 2024-11-09T05:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/trump-s-2024-election-victory-signals-major-shifts-in-us-healthcare-policy 2024-11-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trump-s-2024-election-victory-signals-major-shifts-in-us-healthcare-policy 2024-11-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-dimopoulos-on-efficacy-findings-from-the-dreamm-8-trial-in-multiple-myeloma 2024-11-09T04:54:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-dimopoulos-on-efficacy-findings-from-the-dreamm-8-trial-in-multiple-myeloma 2024-11-09T04:54:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-october-approvals-include-the-first-cldn18-2-mab-biocentury 2024-11-09T04:53:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-october-approvals-include-the-first-cldn18-2-mab-biocentury 2024-11-09T04:53:38+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-multiple-sclerosis-medpage-today 2024-11-09T04:03:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/year-in-review-multiple-sclerosis-medpage-today 2024-11-09T04:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/lurie-children-s-developing-optical-genome-mapping-test-for-brain-tumors 2024-11-09T04:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lurie-children-s-developing-optical-genome-mapping-test-for-brain-tumors 2024-11-09T04:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/donanemab-small-tweak-in-titration-big-gain-in-safety-alzforum 2024-11-09T03:21:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/donanemab-small-tweak-in-titration-big-gain-in-safety-alzforum 2024-11-09T03:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/huyabio-presents-positive-phase-2-data-on-hbi-8000-and-nivolumab-combination-for 2024-11-09T03:15:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/huyabio-presents-positive-phase-2-data-on-hbi-8000-and-nivolumab-combination-for 2024-11-09T03:15:10+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-biospace 2024-11-09T03:15:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-biospace 2024-11-09T03:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-biospace 2024-11-09T03:15:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-biospace 2024-11-09T03:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024 2024-11-09T03:15:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024 2024-11-09T03:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/sec-recommends-approval-for-msn-laboratories-sleep-disorder-drug-pharmabiz-com 2024-11-09T02:29:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sec-recommends-approval-for-msn-laboratories-sleep-disorder-drug-pharmabiz-com 2024-11-09T02:29:50+00:00 weekly 0.7 https://trial.medpath.com/news/dostarlimab-plus-chemo-yield-strong-survival-results-in-metastatic-nsclc 2024-11-09T02:22:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dostarlimab-plus-chemo-yield-strong-survival-results-in-metastatic-nsclc 2024-11-09T02:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-offers-new-hope-for-weight-loss-seekers-local-12 2024-11-09T02:13:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-offers-new-hope-for-weight-loss-seekers-local-12 2024-11-09T02:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/bioatla-inc-bcab-q3-2024-earnings-call-highlights-strategic-a-gurufocus 2024-11-09T01:58:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioatla-inc-bcab-q3-2024-earnings-call-highlights-strategic-a-gurufocus 2024-11-09T01:58:49+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-ai-unveils-breakthrough-cancer-treatment-algorithm-cost-saving-study-at-sitc-2024 2024-11-09T00:47:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempus-ai-unveils-breakthrough-cancer-treatment-algorithm-cost-saving-study-at-sitc-2024 2024-11-09T00:47:44+00:00 weekly 0.7 https://trial.medpath.com/news/ntla-2002-gene-editing-reduces-angioedema-attacks-in-hereditary-angioedema 2024-11-09T00:09:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ntla-2002-gene-editing-reduces-angioedema-attacks-in-hereditary-angioedema 2024-11-09T00:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial 2024-11-09T00:02:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial 2024-11-09T00:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-on-alzheimer-s-disease-ctad-2023-16th-alzforum 2024-11-09T00:00:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-on-alzheimer-s-disease-ctad-2023-16th-alzforum 2024-11-09T00:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-r-pembrolizumab-significantly 2024-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-keytruda-r-pembrolizumab-significantly 2024-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-statement-on-fda-advisory-committee-meeting-for-zinplava 2024-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-statement-on-fda-advisory-committee-meeting-for-zinplava 2024-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-phase-iii-nasal-polyp-data-may-lead-to-second-indication-citeline 2024-11-08T23:18:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-phase-iii-nasal-polyp-data-may-lead-to-second-indication-citeline 2024-11-08T23:18:30+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-gets-fda-approval-for-cancer-treatment-morningstar 2024-11-08T23:06:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-therapeutics-gets-fda-approval-for-cancer-treatment-morningstar 2024-11-08T23:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/evolving-role-of-mrd-status-in-multiple-myeloma-the-asco-post 2024-11-08T23:01:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolving-role-of-mrd-status-in-multiple-myeloma-the-asco-post 2024-11-08T23:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obecabtagene-autoleucel-for-adult-leukemia-treatment-healio 2024-11-08T22:59:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-obecabtagene-autoleucel-for-adult-leukemia-treatment-healio 2024-11-08T22:59:10+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-s-amylin-obesity-drug-could-rival-novo-s-but-it-needs-a-partner-citeline 2024-11-08T22:52:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zealand-s-amylin-obesity-drug-could-rival-novo-s-but-it-needs-a-partner-citeline 2024-11-08T22:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/3-latest-medical-breakthroughs-to-know-about-in-2024 2024-11-08T22:45:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-latest-medical-breakthroughs-to-know-about-in-2024 2024-11-08T22:45:07+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-plc-tezspire-meets-primary-endpoints-in-waypoint-trial 2024-11-08T22:21:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-plc-tezspire-meets-primary-endpoints-in-waypoint-trial 2024-11-08T22:21:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obe-cel-for-adults-with-r-r-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-08T22:19:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-obe-cel-for-adults-with-r-r-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-08T22:19:14+00:00 weekly 0.7 https://trial.medpath.com/news/eyeing-the-future-of-oncology-highlights-from-the-presidential-symposium-at-esmo-congress-2024 2024-11-08T22:18:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyeing-the-future-of-oncology-highlights-from-the-presidential-symposium-at-esmo-congress-2024 2024-11-08T22:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/unexpected-results-in-solid-tumors-what-we-learned-from-negative-findings 2024-11-08T22:18:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unexpected-results-in-solid-tumors-what-we-learned-from-negative-findings 2024-11-08T22:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-aucatzyl-for-adults-with-aggressive-leukemia 2024-11-08T22:15:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-aucatzyl-for-adults-with-aggressive-leukemia 2024-11-08T22:15:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obe-cel-for-r-r-b-cell-acute-lymphoblastic-leukemia 2024-11-08T22:05:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-obe-cel-for-r-r-b-cell-acute-lymphoblastic-leukemia 2024-11-08T22:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/positive-trials-continue-to-shape-the-sclc-treatment-landscape-targeted-oncology 2024-11-08T22:05:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-trials-continue-to-shape-the-sclc-treatment-landscape-targeted-oncology 2024-11-08T22:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obecabtagene-autoleucel-for-relapsed-refractory-b-cell-precursor-all 2024-11-08T22:01:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-obecabtagene-autoleucel-for-relapsed-refractory-b-cell-precursor-all 2024-11-08T22:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-renews-authorization-for-eight-general-snus-products-nacs 2024-11-08T21:50:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-renews-authorization-for-eight-general-snus-products-nacs 2024-11-08T21:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-08T21:42:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-08T21:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-car-t-cell-therapy-for-relapsed-or-refractory-b-cell-all-cure-today 2024-11-08T21:41:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-car-t-cell-therapy-for-relapsed-or-refractory-b-cell-all-cure-today 2024-11-08T21:41:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obecabtagene-autoleucel-in-b-cell-all-cancer-network 2024-11-08T21:27:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-obecabtagene-autoleucel-in-b-cell-all-cancer-network 2024-11-08T21:27:57+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-08T21:26:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-08T21:26:53+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-globenewswire 2024-11-08T21:25:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-globenewswire 2024-11-08T21:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-obecabtagene-autoleucel-for-r-r-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-08T21:18:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-obecabtagene-autoleucel-for-r-r-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-08T21:18:32+00:00 weekly 0.7 https://trial.medpath.com/news/ima203-shows-frequent-enduring-responses-and-tolerability-in-melanoma 2024-11-08T21:17:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ima203-shows-frequent-enduring-responses-and-tolerability-in-melanoma 2024-11-08T21:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/kiromic-biopharma-inc-sec-10-q-report-tradingview 2024-11-08T21:16:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kiromic-biopharma-inc-sec-10-q-report-tradingview 2024-11-08T21:16:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-aucatzyl-obecabtagene-autoleucel-for-adults-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia 2024-11-08T21:11:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-aucatzyl-obecabtagene-autoleucel-for-adults-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia 2024-11-08T21:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-successful-phase-iii-trial-for-tezspire-marketscreener 2024-11-08T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-successful-phase-iii-trial-for-tezspire-marketscreener 2024-11-08T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-greenlights-obe-cel-in-relapsed-refractory-b-all-targeted-oncology 2024-11-08T21:05:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-greenlights-obe-cel-in-relapsed-refractory-b-all-targeted-oncology 2024-11-08T21:05:22+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-therapy-yields-notable-outcomes-in-triple-negative-breast-cancer 2024-11-08T21:00:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-therapy-yields-notable-outcomes-in-triple-negative-breast-cancer 2024-11-08T21:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/cue-biopharma-presents-positive-updated-data-from-its-phase-1-trials-of-cue-101-biospace 2024-11-08T20:57:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cue-biopharma-presents-positive-updated-data-from-its-phase-1-trials-of-cue-101-biospace 2024-11-08T20:57:40+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-dostarlimab-chemo-maintains-numerical-os-benefit-in-advanced-nsclc 2024-11-08T20:49:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontline-dostarlimab-chemo-maintains-numerical-os-benefit-in-advanced-nsclc 2024-11-08T20:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-for-new-indications-for-darzalex-markets-insider 2024-11-08T20:15:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-submits-applications-for-new-indications-for-darzalex-markets-insider 2024-11-08T20:15:39+00:00 weekly 0.7 https://trial.medpath.com/news/former-fitness-instructor-beyond-excited-to-receive-lupus-therapy-in-uk-first 2024-11-08T20:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/former-fitness-instructor-beyond-excited-to-receive-lupus-therapy-in-uk-first 2024-11-08T20:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-and-amgen-s-tezspire-succeeds-in-phase-iii-nasal-polyps-trial 2024-11-08T19:55:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-and-amgen-s-tezspire-succeeds-in-phase-iii-nasal-polyps-trial 2024-11-08T19:55:42+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap 2024-11-08T19:38:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap 2024-11-08T19:38:56+00:00 weekly 0.7 https://trial.medpath.com/news/remembering-bruce-albala-70-leader-in-bace-inhibitor-development-alzforum 2024-11-08T19:31:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remembering-bruce-albala-70-leader-in-bace-inhibitor-development-alzforum 2024-11-08T19:31:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-takes-step-toward-removal-of-ineffective-decongestants-from-the-market 2024-11-08T18:56:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-takes-step-toward-removal-of-ineffective-decongestants-from-the-market 2024-11-08T18:56:12+00:00 weekly 0.7 https://trial.medpath.com/news/cue-biopharma-cancer-drug-trial-soars-91-survival-rate-shatters-expectations 2024-11-08T18:54:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cue-biopharma-cancer-drug-trial-soars-91-survival-rate-shatters-expectations 2024-11-08T18:54:57+00:00 weekly 0.7 https://trial.medpath.com/news/senseonics-has-mixed-q3-results-positive-eversense-365-outlook-drug-delivery-business 2024-11-08T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senseonics-has-mixed-q3-results-positive-eversense-365-outlook-drug-delivery-business 2024-11-08T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/cue-biopharma-presents-positive-updated-data-from-its-phase-globenewswire 2024-11-08T18:46:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cue-biopharma-presents-positive-updated-data-from-its-phase-globenewswire 2024-11-08T18:46:28+00:00 weekly 0.7 https://trial.medpath.com/news/uk-study-shows-rsv-vaccine-could-reduce-antibiotic-use-and-antimicrobial-resistance 2024-11-08T18:28:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-study-shows-rsv-vaccine-could-reduce-antibiotic-use-and-antimicrobial-resistance 2024-11-08T18:28:29+00:00 weekly 0.7 https://trial.medpath.com/news/cmn-weekly-8-november-2024-your-weekly-crispr-medicine-news 2024-11-08T18:26:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cmn-weekly-8-november-2024-your-weekly-crispr-medicine-news 2024-11-08T18:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-us-fda-tentative-approval-for-raltegravir-tablets-usp-pharmabiz-com 2024-11-08T18:25:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupin-receives-us-fda-tentative-approval-for-raltegravir-tablets-usp-pharmabiz-com 2024-11-08T18:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-reveals-promising-phase-2-trial-results-tipranks-com 2024-11-08T18:20:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-reveals-promising-phase-2-trial-results-tipranks-com 2024-11-08T18:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/sunvozertinib-nda-submitted-to-fda-for-nsclc 2024-11-08T18:20:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sunvozertinib-nda-submitted-to-fda-for-nsclc 2024-11-08T18:20:13+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-launches-institute-for-cell-therapy-discovery-innovation-to-deliver 2024-11-08T18:15:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-launches-institute-for-cell-therapy-discovery-innovation-to-deliver 2024-11-08T18:15:37+00:00 weekly 0.7 https://trial.medpath.com/news/kiora-pharmaceuticals-reports-third-quarter-results-retinal-disease-pipeline-advancing 2024-11-08T18:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kiora-pharmaceuticals-reports-third-quarter-results-retinal-disease-pipeline-advancing 2024-11-08T18:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/ondine-biomedical-life-sciences-company-raises-c-16-million-pulse-2-0 2024-11-08T18:00:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ondine-biomedical-life-sciences-company-raises-c-16-million-pulse-2-0 2024-11-08T18:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-disease-what-treatments-could-be-rolled-out-in-the-next-few-years-the-bmj 2024-11-08T17:48:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-disease-what-treatments-could-be-rolled-out-in-the-next-few-years-the-bmj 2024-11-08T17:48:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-sought-for-sunvozertinib-in-pretreated-egfr-exon-20-advanced-nsclc 2024-11-08T17:38:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-sought-for-sunvozertinib-in-pretreated-egfr-exon-20-advanced-nsclc 2024-11-08T17:38:34+00:00 weekly 0.7 https://trial.medpath.com/news/modified-kisunla-dosing-lowers-risk-of-aria-e-in-alzheimer-s-study 2024-11-08T17:10:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/modified-kisunla-dosing-lowers-risk-of-aria-e-in-alzheimer-s-study 2024-11-08T17:10:31+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T17:09:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T17:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/kineta-updates-kva12123-clinical-results-from-ongoing-phase-1-2-vista101-study-at 2024-11-08T17:09:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kineta-updates-kva12123-clinical-results-from-ongoing-phase-1-2-vista101-study-at 2024-11-08T17:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m17d1-in-advanced 2024-11-08T17:09:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m17d1-in-advanced 2024-11-08T17:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/monopar-therapeutics-reports-third-quarter-2024-financial-results-and-recent-developments 2024-11-08T17:09:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monopar-therapeutics-reports-third-quarter-2024-financial-results-and-recent-developments 2024-11-08T17:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-launches-institute-for-cell-therapy-di-newswise 2024-11-08T17:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-launches-institute-for-cell-therapy-di-newswise 2024-11-08T17:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/fda-ema-receive-applications-for-subcutaneous-daratumumab-in-myeloma 2024-11-08T17:07:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-ema-receive-applications-for-subcutaneous-daratumumab-in-myeloma 2024-11-08T17:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/mb-108-gains-fda-orphan-drug-status-for-malignant-glioma-treatment 2024-11-08T17:05:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mb-108-gains-fda-orphan-drug-status-for-malignant-glioma-treatment 2024-11-08T17:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/hurricane-helene-delays-spectral-medical-s-confirmatory-trial-enrolment 2024-11-08T16:59:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hurricane-helene-delays-spectral-medical-s-confirmatory-trial-enrolment 2024-11-08T16:59:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-plans-to-ban-ineffective-cold-medicine-ingredient-how-it-will-affect-you-health 2024-11-08T16:52:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-plans-to-ban-ineffective-cold-medicine-ingredient-how-it-will-affect-you-health 2024-11-08T16:52:17+00:00 weekly 0.7 https://trial.medpath.com/news/relmada-therapeutics-hopes-to-hit-big-milestones-by-year-end 2024-11-08T16:50:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relmada-therapeutics-hopes-to-hit-big-milestones-by-year-end 2024-11-08T16:50:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-ifetroban-for-treatment-of-duchenne-muscular 2024-11-08T16:46:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-ifetroban-for-treatment-of-duchenne-muscular 2024-11-08T16:46:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-ema-receive-applications-for-subcutaneous-daratumumab-in-high-risk-smoldering-myeloma 2024-11-08T16:43:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-ema-receive-applications-for-subcutaneous-daratumumab-in-high-risk-smoldering-myeloma 2024-11-08T16:43:51+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T16:40:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T16:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-succeeds-in-chronic-rhinosinusitis-gilead-writes-down-trodelvy-value 2024-11-08T16:38:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-succeeds-in-chronic-rhinosinusitis-gilead-writes-down-trodelvy-value 2024-11-08T16:38:32+00:00 weekly 0.7 https://trial.medpath.com/news/oncoresponse-reports-data-of-phase-i-solid-tumour-treatment-trial-clinical-trials-arena 2024-11-08T16:24:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncoresponse-reports-data-of-phase-i-solid-tumour-treatment-trial-clinical-trials-arena 2024-11-08T16:24:31+00:00 weekly 0.7 https://trial.medpath.com/news/alignment-extending-our-clinical-trials-to-more-patients-yale-school-of-medicine 2024-11-08T16:22:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alignment-extending-our-clinical-trials-to-more-patients-yale-school-of-medicine 2024-11-08T16:22:03+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-s-varipulse-platform-receives-fda-approval-for-afib 2024-11-08T16:14:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-medtech-s-varipulse-platform-receives-fda-approval-for-afib 2024-11-08T16:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/les-turner-symposium-on-als-unites-community-around-research-and-patient-care 2024-11-08T16:05:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/les-turner-symposium-on-als-unites-community-around-research-and-patient-care 2024-11-08T16:05:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-johnson-johnson-s-varipulse-for-drug-resistant-paroxysmal-atrial-fibrillation 2024-11-08T15:47:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-johnson-johnson-s-varipulse-for-drug-resistant-paroxysmal-atrial-fibrillation 2024-11-08T15:47:56+00:00 weekly 0.7 https://trial.medpath.com/news/trastuzumab-duocarmazine-in-previously-treated-her2-positive-metastatic-breast-cancer 2024-11-08T15:44:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trastuzumab-duocarmazine-in-previously-treated-her2-positive-metastatic-breast-cancer 2024-11-08T15:44:48+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-awarded-the-prix-galien-usa-2024-prize-for-best-startup-the-globe-and-mail 2024-11-08T15:40:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cervomed-awarded-the-prix-galien-usa-2024-prize-for-best-startup-the-globe-and-mail 2024-11-08T15:40:22+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-ipilimumab-in-aggressive-thyroid-carcinoma-the-asco-post 2024-11-08T15:37:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-plus-ipilimumab-in-aggressive-thyroid-carcinoma-the-asco-post 2024-11-08T15:37:23+00:00 weekly 0.7 https://trial.medpath.com/news/sunvozertinib-new-drug-application-in-egfr-mutant-nsclc-submitted-to-fda 2024-11-08T15:35:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sunvozertinib-new-drug-application-in-egfr-mutant-nsclc-submitted-to-fda 2024-11-08T15:35:34+00:00 weekly 0.7 https://trial.medpath.com/news/compass-therapeutics-reveals-breakthrough-biomarker-data-for-cancer-drug-ctx-471 2024-11-08T15:15:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/compass-therapeutics-reveals-breakthrough-biomarker-data-for-cancer-drug-ctx-471 2024-11-08T15:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-rosacea-treatment-proposal-to-remove-oral-phenylephrine-from-otc-products 2024-11-08T15:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-roundup-rosacea-treatment-proposal-to-remove-oral-phenylephrine-from-otc-products 2024-11-08T15:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/pediatric-gastroparesis-hospitalizations-surge-post-covid-19-chop-study-reveals 2024-11-08T15:06:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pediatric-gastroparesis-hospitalizations-surge-post-covid-19-chop-study-reveals 2024-11-08T15:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-approval-of-darzalex-faspro-in-us-darzalex-in-eu-for-myeloma 2024-11-08T15:05:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-approval-of-darzalex-faspro-in-us-darzalex-in-eu-for-myeloma 2024-11-08T15:05:58+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-rsv-medpage-today 2024-11-08T15:01:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/year-in-review-rsv-medpage-today 2024-11-08T15:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/dogwood-therapeutics-inc-sec-10-q-report-tradingview 2024-11-08T15:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dogwood-therapeutics-inc-sec-10-q-report-tradingview 2024-11-08T15:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T15:00:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T15:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/skyrizi-overtakes-humira-in-u-s-sales-numbers-managed-healthcare-executive 2024-11-08T15:00:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skyrizi-overtakes-humira-in-u-s-sales-numbers-managed-healthcare-executive 2024-11-08T15:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/expert-comments-on-the-risks-and-benefits-of-tirzepatide-following-the-death-of-susan-mcgowan 2024-11-08T14:56:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-comments-on-the-risks-and-benefits-of-tirzepatide-following-the-death-of-susan-mcgowan 2024-11-08T14:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/uclh-announces-start-of-car-t-cell-therapy-clinical-trial-for-lupus-patients 2024-11-08T14:38:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uclh-announces-start-of-car-t-cell-therapy-clinical-trial-for-lupus-patients 2024-11-08T14:38:41+00:00 weekly 0.7 https://trial.medpath.com/news/aurinia-slashes-workforce-by-45-to-focus-on-lupus-and-autoimmune-assets 2024-11-08T14:35:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aurinia-slashes-workforce-by-45-to-focus-on-lupus-and-autoimmune-assets 2024-11-08T14:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-to-pull-common-but-ineffective-cold-medicine-from-market-cbs-news 2024-11-08T14:33:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-to-pull-common-but-ineffective-cold-medicine-from-market-cbs-news 2024-11-08T14:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/iag-beats-on-q3-revenue-astrazeneca-discloses-positive-phase-3-clinical-trial 2024-11-08T14:28:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iag-beats-on-q3-revenue-astrazeneca-discloses-positive-phase-3-clinical-trial 2024-11-08T14:28:50+00:00 weekly 0.7 https://trial.medpath.com/news/extrachromosomal-dna-spread-oncogenic-traits-add-synthetic-lethal-targets 2024-11-08T14:27:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/extrachromosomal-dna-spread-oncogenic-traits-add-synthetic-lethal-targets 2024-11-08T14:27:20+00:00 weekly 0.7 https://trial.medpath.com/news/lakeshore-commences-bla-submission-to-drap-for-rabies-vaccine 2024-11-08T14:25:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lakeshore-commences-bla-submission-to-drap-for-rabies-vaccine 2024-11-08T14:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/cidara-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-08T14:22:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cidara-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-08T14:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-s-cancer-biomarker-test-outshines-standard-ici-predictive-tests 2024-11-08T14:20:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cofactor-s-cancer-biomarker-test-outshines-standard-ici-predictive-tests 2024-11-08T14:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic-rhinosinusitis-with-nasal-polyps 2024-11-08T14:17:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic-rhinosinusitis-with-nasal-polyps 2024-11-08T14:17:50+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:15:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:15:53+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:14:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:14:59+00:00 weekly 0.7 https://trial.medpath.com/news/biostock-full-phase-ii-results-of-upar-pet-in-glioblastoma-published-cision-news 2024-11-08T14:09:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biostock-full-phase-ii-results-of-upar-pet-in-glioblastoma-published-cision-news 2024-11-08T14:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:06:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:06:59+00:00 weekly 0.7 https://trial.medpath.com/news/luspatercept-improved-diagnostics-deliver-in-mds-targeted-oncology 2024-11-08T14:05:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/luspatercept-improved-diagnostics-deliver-in-mds-targeted-oncology 2024-11-08T14:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-the-first-flu-vaccine-for-at-home-use-providing-a-needle-free-option-akin-gump 2024-11-08T13:45:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-the-first-flu-vaccine-for-at-home-use-providing-a-needle-free-option-akin-gump 2024-11-08T13:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-marketing-for-first-combination-flu-and-covid-19-at-home-test-outside-of 2024-11-08T13:45:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-authorizes-marketing-for-first-combination-flu-and-covid-19-at-home-test-outside-of 2024-11-08T13:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-therapy-with-potential-to-transform-lupus-treatment-delivered-in-manchester-in-uk-first 2024-11-08T13:41:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-therapy-with-potential-to-transform-lupus-treatment-delivered-in-manchester-in-uk-first 2024-11-08T13:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-says-phase-iii-waypoint-study-of-tezspire-met-primary-goals-rttnews 2024-11-08T13:41:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-says-phase-iii-waypoint-study-of-tezspire-met-primary-goals-rttnews 2024-11-08T13:41:39+00:00 weekly 0.7 https://trial.medpath.com/news/springworks-therapeutics-announces-long-term-efficacy-and-safety-data-from-phase-3 2024-11-08T13:40:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springworks-therapeutics-announces-long-term-efficacy-and-safety-data-from-phase-3 2024-11-08T13:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/xilio-therapeutics-announces-initial-clinical-trial-data-from-phase-1c-dose-escalation-biospace 2024-11-08T13:40:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xilio-therapeutics-announces-initial-clinical-trial-data-from-phase-1c-dose-escalation-biospace 2024-11-08T13:40:56+00:00 weekly 0.7 https://trial.medpath.com/news/immunovant-provides-development-updates-and-reports-financial-results-for-the-quarter 2024-11-08T13:40:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunovant-provides-development-updates-and-reports-financial-results-for-the-quarter 2024-11-08T13:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic 2024-11-08T13:40:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic 2024-11-08T13:40:53+00:00 weekly 0.7 https://trial.medpath.com/news/achieve-life-sciences-reports-financial-results-for-third-quarter-2024-and-provides 2024-11-08T13:40:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/achieve-life-sciences-reports-financial-results-for-third-quarter-2024-and-provides 2024-11-08T13:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-medtech-receives-us-fda-approval-for-varipulse-pfa-platform-in-af-treatment 2024-11-08T13:30:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-medtech-receives-us-fda-approval-for-varipulse-pfa-platform-in-af-treatment 2024-11-08T13:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-j-j-s-device-for-heart-condition-healthleaders-media 2024-11-08T13:28:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-j-j-s-device-for-heart-condition-healthleaders-media 2024-11-08T13:28:38+00:00 weekly 0.7 https://trial.medpath.com/news/mariposa-2-second-interim-survival-data-targeted-oncology 2024-11-08T13:20:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mariposa-2-second-interim-survival-data-targeted-oncology 2024-11-08T13:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/ncats-award-to-support-multi-site-study-evaluating-remote-trials-university-at-buffalo 2024-11-08T13:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ncats-award-to-support-multi-site-study-evaluating-remote-trials-university-at-buffalo 2024-11-08T13:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/minn-ems-looks-to-enroll-trauma-patients-in-blood-loss-drug-trials-ems1 2024-11-08T13:15:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minn-ems-looks-to-enroll-trauma-patients-in-blood-loss-drug-trials-ems1 2024-11-08T13:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seek-approval-of-darzalex 2024-11-08T13:14:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seek-approval-of-darzalex 2024-11-08T13:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/cleveland-clinic-announces-updated-findings-in-preventive-breast-cancer-vaccine-study 2024-11-08T13:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cleveland-clinic-announces-updated-findings-in-preventive-breast-cancer-vaccine-study 2024-11-08T13:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-fda-ema-nod-for-myeloma-treatment-investing-com 2024-11-08T12:51:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-fda-ema-nod-for-myeloma-treatment-investing-com 2024-11-08T12:51:53+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-and-amgen-s-tezspire-succeeds-in-phase-iii-nasal-polyps-trial 2024-11-08T12:46:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-and-amgen-s-tezspire-succeeds-in-phase-iii-nasal-polyps-trial 2024-11-08T12:46:19+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:41:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflarx-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/south-africa-becomes-a-key-player-in-astrazeneca-s-global-clinical-trial-success 2024-11-08T12:41:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/south-africa-becomes-a-key-player-in-astrazeneca-s-global-clinical-trial-success 2024-11-08T12:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/meeting-highlights-from-the-committee-for-veterinary-medicinal-products-cvmp-5-7 2024-11-08T12:40:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meeting-highlights-from-the-committee-for-veterinary-medicinal-products-cvmp-5-7 2024-11-08T12:40:25+00:00 weekly 0.7 https://trial.medpath.com/news/icecure-s-prosense-cancer-treatment-wins-crucial-fda-panel-vote-shares-surge 2024-11-08T12:37:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icecure-s-prosense-cancer-treatment-wins-crucial-fda-panel-vote-shares-surge 2024-11-08T12:37:24+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-sglt2i-drugs-are-safe-for-patients-with-cirrhosis-consult-qd 2024-11-08T12:35:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-sglt2i-drugs-are-safe-for-patients-with-cirrhosis-consult-qd 2024-11-08T12:35:22+00:00 weekly 0.7 https://trial.medpath.com/news/who-announces-priority-endemic-pathogens-for-urgent-vaccine-development-pmlive 2024-11-08T12:28:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-announces-priority-endemic-pathogens-for-urgent-vaccine-development-pmlive 2024-11-08T12:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-tezspire-shows-promise-in-phase-iii-trial-markets-insider 2024-11-08T12:24:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-tezspire-shows-promise-in-phase-iii-trial-markets-insider 2024-11-08T12:24:49+00:00 weekly 0.7 https://trial.medpath.com/news/uk-study-shows-rsv-vaccine-could-reduce-antibiotic-use-and-antimicrobial-resistance 2024-11-08T12:23:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-study-shows-rsv-vaccine-could-reduce-antibiotic-use-and-antimicrobial-resistance 2024-11-08T12:23:56+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T12:23:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T12:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T12:21:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T12:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus 2024-11-08T12:13:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus 2024-11-08T12:13:54+00:00 weekly 0.7 https://trial.medpath.com/news/akero-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:13:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akero-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/the-uk-developed-handheld-scanner-that-could-revolutionise-medical-imaging-the-engineer 2024-11-08T12:11:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-uk-developed-handheld-scanner-that-could-revolutionise-medical-imaging-the-engineer 2024-11-08T12:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/akero-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:10:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akero-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-globenewswire 2024-11-08T12:10:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-globenewswire 2024-11-08T12:10:24+00:00 weekly 0.7 https://trial.medpath.com/news/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus 2024-11-08T12:10:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus 2024-11-08T12:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-pr-newswire 2024-11-08T12:00:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-pr-newswire 2024-11-08T12:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/averitas-completes-recruitment-for-trial-of-qutenza-to-treat-post-surgical-pain 2024-11-08T12:00:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/averitas-completes-recruitment-for-trial-of-qutenza-to-treat-post-surgical-pain 2024-11-08T12:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/averitas-completes-recruitment-for-trial-of-qutenza-to-treat-post-surgical-pain 2024-11-08T11:58:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/averitas-completes-recruitment-for-trial-of-qutenza-to-treat-post-surgical-pain 2024-11-08T11:58:29+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-care-evolution-industry-leaders-address-quadruple-aim-challenges-and-opportunities 2024-11-08T11:53:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-care-evolution-industry-leaders-address-quadruple-aim-challenges-and-opportunities 2024-11-08T11:53:41+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-provides-business-update-with-third-quarter-2024-financial-results-globenewswire 2024-11-08T11:48:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-provides-business-update-with-third-quarter-2024-financial-results-globenewswire 2024-11-08T11:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-pharmaceutical-co-ltd-submits-new-drug-application-to-the-u-s-fda-for-marketscreener 2024-11-08T11:43:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dizal-pharmaceutical-co-ltd-submits-new-drug-application-to-the-u-s-fda-for-marketscreener 2024-11-08T11:43:36+00:00 weekly 0.7 https://trial.medpath.com/news/babyfox-study-to-assess-impact-of-ultrafast-whole-genome-sequencing-on-nicu-care-for 2024-11-08T11:42:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/babyfox-study-to-assess-impact-of-ultrafast-whole-genome-sequencing-on-nicu-care-for 2024-11-08T11:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/dicot-pharma-announces-initiation-of-phase-2a-clinical-study-cision-news 2024-11-08T11:37:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dicot-pharma-announces-initiation-of-phase-2a-clinical-study-cision-news 2024-11-08T11:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-s-varipulse-platform-receives-fda-approval-for-afib 2024-11-08T11:34:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-medtech-s-varipulse-platform-receives-fda-approval-for-afib 2024-11-08T11:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/novel-dll3-topabody-shows-promising-preclinical-results-for-small-cell-lung-cancer-treatment 2024-11-08T11:31:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-dll3-topabody-shows-promising-preclinical-results-for-small-cell-lung-cancer-treatment 2024-11-08T11:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-of-multi-tyrosine-kinase-inhibitor-esk981-in-combination-with-pd-1-urotoday 2024-11-08T11:30:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-trial-of-multi-tyrosine-kinase-inhibitor-esk981-in-combination-with-pd-1-urotoday 2024-11-08T11:30:23+00:00 weekly 0.7 https://trial.medpath.com/news/a-36-gene-predictive-score-of-anti-cancer-dru-eurekalert 2024-11-08T11:24:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-36-gene-predictive-score-of-anti-cancer-dru-eurekalert 2024-11-08T11:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed 2024-11-08T11:21:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed 2024-11-08T11:21:31+00:00 weekly 0.7 https://trial.medpath.com/news/recruitment-underway-for-a-clinical-trial-testing-new-vaccine-against-respiratory-viruses 2024-11-08T11:17:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recruitment-underway-for-a-clinical-trial-testing-new-vaccine-against-respiratory-viruses 2024-11-08T11:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-suggests-removing-nonprescription-decongestant-from-market 2024-11-08T11:15:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-suggests-removing-nonprescription-decongestant-from-market 2024-11-08T11:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-announces-successful-completion-of-end-of-phase-2-meeting-with-fda-for 2024-11-08T11:11:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/altimmune-announces-successful-completion-of-end-of-phase-2-meeting-with-fda-for 2024-11-08T11:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/radella-reports-positive-outcomes-from-trial-of-md-18-for-obesity-and-diabetes 2024-11-08T11:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radella-reports-positive-outcomes-from-trial-of-md-18-for-obesity-and-diabetes 2024-11-08T11:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/smallpox-drug-in-clinical-trials-for-treating-mpox-in-africa 2024-11-08T10:41:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/smallpox-drug-in-clinical-trials-for-treating-mpox-in-africa 2024-11-08T10:41:32+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed 2024-11-08T10:16:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed 2024-11-08T10:16:34+00:00 weekly 0.7 https://trial.medpath.com/news/ncc-premia-paradigm-unveil-nationwide-clinical-trial-network-in-japan-healthcare-asia 2024-11-08T10:10:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ncc-premia-paradigm-unveil-nationwide-clinical-trial-network-in-japan-healthcare-asia 2024-11-08T10:10:52+00:00 weekly 0.7 https://trial.medpath.com/news/determining-doses-for-backfill-cohorts-based-on-patient-reported-outcome 2024-11-08T09:35:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/determining-doses-for-backfill-cohorts-based-on-patient-reported-outcome 2024-11-08T09:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/da-expects-approval-of-asf-vaccine-for-commercial-use-by-yearend-abs-cbn-news 2024-11-08T09:33:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/da-expects-approval-of-asf-vaccine-for-commercial-use-by-yearend-abs-cbn-news 2024-11-08T09:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/metabolic-markers-linked-to-cognitive-decline-in-multiple-sclerosis-patients-study-finds 2024-11-08T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metabolic-markers-linked-to-cognitive-decline-in-multiple-sclerosis-patients-study-finds 2024-11-08T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-rises-after-asthma-medicine-meets-primary-goals-in-phase-3-trial-tradingview 2024-11-08T08:31:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-rises-after-asthma-medicine-meets-primary-goals-in-phase-3-trial-tradingview 2024-11-08T08:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-hails-positive-phase-iii-data-for-repurposed-asthma-treatment-lse-azn 2024-11-08T07:54:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-hails-positive-phase-iii-data-for-repurposed-asthma-treatment-lse-azn 2024-11-08T07:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/industry-leaders-unite-to-tackle-patient-recruitment-challenges-in-rare-disease-clinical-trials 2024-11-08T07:53:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/industry-leaders-unite-to-tackle-patient-recruitment-challenges-in-rare-disease-clinical-trials 2024-11-08T07:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/wvu-cancer-institute-first-to-use-fda-approved-device-for-esophageal-cancer-prevention 2024-11-08T07:49:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wvu-cancer-institute-first-to-use-fda-approved-device-for-esophageal-cancer-prevention 2024-11-08T07:49:23+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-tezspire-shows-promise-in-phase-iii-trial-tipranks-com 2024-11-08T07:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-tezspire-shows-promise-in-phase-iii-trial-tipranks-com 2024-11-08T07:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/combining-the-vigex-gene-expression-signature-eurekalert 2024-11-08T07:26:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combining-the-vigex-gene-expression-signature-eurekalert 2024-11-08T07:26:33+00:00 weekly 0.7 https://trial.medpath.com/news/dr-ashraf-on-the-utility-of-t-dxd-in-her2-mutated-nsclc-onclive 2024-11-08T07:23:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-ashraf-on-the-utility-of-t-dxd-in-her2-mutated-nsclc-onclive 2024-11-08T07:23:43+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic 2024-11-08T07:13:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic 2024-11-08T07:13:30+00:00 weekly 0.7 https://trial.medpath.com/news/fox-chase-cancer-center-appoints-renowned-immunotherapy-expert-dr-lorenzo-galluzzi-as-associate-professor 2024-11-08T07:08:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fox-chase-cancer-center-appoints-renowned-immunotherapy-expert-dr-lorenzo-galluzzi-as-associate-professor 2024-11-08T07:08:52+00:00 weekly 0.7 https://trial.medpath.com/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T07:04:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T07:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/ciie-helping-gilead-sciences-boost-development-in-china-chinadaily-com-cn 2024-11-08T06:56:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ciie-helping-gilead-sciences-boost-development-in-china-chinadaily-com-cn 2024-11-08T06:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/skye-bioscience-reports-progress-in-obesity-drug-trials-tipranks-com 2024-11-08T06:45:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skye-bioscience-reports-progress-in-obesity-drug-trials-tipranks-com 2024-11-08T06:45:45+00:00 weekly 0.7 https://trial.medpath.com/news/egetis-therapeutics-interim-report-q3-2024-mfn-placera 2024-11-08T06:05:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/egetis-therapeutics-interim-report-q3-2024-mfn-placera 2024-11-08T06:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-how-patients-and-scientists-team-up-to-fight-cancer-north-bay-news 2024-11-08T06:01:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-how-patients-and-scientists-team-up-to-fight-cancer-north-bay-news 2024-11-08T06:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/positive-outlook-and-buy-rating-for-protagonist-therapeutics-based-on-promising-phase-iii 2024-11-08T05:53:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-outlook-and-buy-rating-for-protagonist-therapeutics-based-on-promising-phase-iii 2024-11-08T05:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/after-decades-fda-finally-moves-to-pull-ineffective-decongestant-off-shelves-ars-technica 2024-11-08T05:44:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/after-decades-fda-finally-moves-to-pull-ineffective-decongestant-off-shelves-ars-technica 2024-11-08T05:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-johnson-johnson-s-device-for-heart-condition-et-healthworld 2024-11-08T05:43:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-johnson-johnson-s-device-for-heart-condition-et-healthworld 2024-11-08T05:43:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-adds-new-warning-to-weight-loss-drugs-including-wegovy-dallas-morning-news 2024-11-08T05:43:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-adds-new-warning-to-weight-loss-drugs-including-wegovy-dallas-morning-news 2024-11-08T05:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-of-j-j-s-varipulse-ramps-up-pfa-competition-bioworld 2024-11-08T04:57:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-of-j-j-s-varipulse-ramps-up-pfa-competition-bioworld 2024-11-08T04:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/nebraska-medicine-finds-success-with-first-of-its-kind-cancer-treatment-wowt 2024-11-08T04:50:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nebraska-medicine-finds-success-with-first-of-its-kind-cancer-treatment-wowt 2024-11-08T04:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-reports-third-quarter-2024-financial-results-biospace 2024-11-08T04:43:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-reports-third-quarter-2024-financial-results-biospace 2024-11-08T04:43:26+00:00 weekly 0.7 https://trial.medpath.com/news/lupus-breakthrough-as-groundbreaking-new-nhs-therapy-could-offer-cure-for-it-and-ms 2024-11-08T04:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupus-breakthrough-as-groundbreaking-new-nhs-therapy-could-offer-cure-for-it-and-ms 2024-11-08T04:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/palleon-pharmaceuticals-presents-results-from-the-phase-1-2-glimmer-01-trial-of-e-602-in-combination-with-cemiplimab-in-patients-with-solid-tumors-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting 2024-11-08T03:11:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palleon-pharmaceuticals-presents-results-from-the-phase-1-2-glimmer-01-trial-of-e-602-in-combination-with-cemiplimab-in-patients-with-solid-tumors-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting 2024-11-08T03:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed-or-refractory-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2024-11-08T03:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed-or-refractory-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2024-11-08T03:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/dr-pedro-martinez-clark-founder-of-amavita-heart-and-vasculartm-partners-with-limflow 2024-11-08T03:08:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-pedro-martinez-clark-founder-of-amavita-heart-and-vasculartm-partners-with-limflow 2024-11-08T03:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/atossa-s-endoxifen-shows-promise-in-reducing-mammographic-breast-density-in-phase-ii-trial 2024-11-08T02:31:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atossa-s-endoxifen-shows-promise-in-reducing-mammographic-breast-density-in-phase-ii-trial 2024-11-08T02:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/sec-recommends-marketing-approval-for-dr-reddy-s-spms-drug-siponimod-tablets 2024-11-08T02:29:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sec-recommends-marketing-approval-for-dr-reddy-s-spms-drug-siponimod-tablets 2024-11-08T02:29:20+00:00 weekly 0.7 https://trial.medpath.com/news/why-imugene-neuren-sigma-and-smartgroup-shares-are-charging-higher-motley-fool 2024-11-08T02:16:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-imugene-neuren-sigma-and-smartgroup-shares-are-charging-higher-motley-fool 2024-11-08T02:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/xilio-therapeutics-announces-initial-clinical-trial-data-globenewswire 2024-11-08T02:16:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xilio-therapeutics-announces-initial-clinical-trial-data-globenewswire 2024-11-08T02:16:07+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-08T02:05:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longboard-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-08T02:05:43+00:00 weekly 0.7 https://trial.medpath.com/news/avidity-biosciences-initiates-biomarker-cohort-in-phase-1-2-fortitude-trial-seeks 2024-11-08T02:02:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avidity-biosciences-initiates-biomarker-cohort-in-phase-1-2-fortitude-trial-seeks 2024-11-08T02:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-china-president-detained-amid-widening-investigation-into-drug-related-violations 2024-11-08T01:45:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-china-president-detained-amid-widening-investigation-into-drug-related-violations 2024-11-08T01:45:11+00:00 weekly 0.7 https://trial.medpath.com/news/rezolute-reports-first-quarter-fiscal-2025-financial-results-and-provides-business-update 2024-11-08T01:32:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rezolute-reports-first-quarter-fiscal-2025-financial-results-and-provides-business-update 2024-11-08T01:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/data-from-transgene-and-nec-confirm-proof-of-principle-for-cancer-vaccine-tg4050 2024-11-08T01:05:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-from-transgene-and-nec-confirm-proof-of-principle-for-cancer-vaccine-tg4050 2024-11-08T01:05:49+00:00 weekly 0.7 https://trial.medpath.com/news/imugene-opens-first-australian-site-for-azer-cel-clinical-trial-targeting-lymphoma 2024-11-08T00:51:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imugene-opens-first-australian-site-for-azer-cel-clinical-trial-targeting-lymphoma 2024-11-08T00:51:58+00:00 weekly 0.7 https://trial.medpath.com/news/dr-parikh-on-available-treatment-options-for-her2-crc-onclive 2024-11-08T00:40:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-parikh-on-available-treatment-options-for-her2-crc-onclive 2024-11-08T00:40:23+00:00 weekly 0.7 https://trial.medpath.com/news/dr-powell-on-the-implications-of-the-fda-approval-of-dostarlimab-for-endometrial-cancer 2024-11-08T00:40:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-powell-on-the-implications-of-the-fda-approval-of-dostarlimab-for-endometrial-cancer 2024-11-08T00:40:04+00:00 weekly 0.7 https://trial.medpath.com/news/three-patient-receive-groundbreaking-lupus-treatment-in-the-uk-the-independent 2024-11-08T00:18:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-patient-receive-groundbreaking-lupus-treatment-in-the-uk-the-independent 2024-11-08T00:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-benmelstobart-plus-anlotinib-and-chemotherapy-in-advanced-or-metastatic-nature 2024-11-08T00:14:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-line-benmelstobart-plus-anlotinib-and-chemotherapy-in-advanced-or-metastatic-nature 2024-11-08T00:14:25+00:00 weekly 0.7 https://trial.medpath.com/news/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus-wandsworth-times 2024-11-08T00:13:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus-wandsworth-times 2024-11-08T00:13:52+00:00 weekly 0.7 https://trial.medpath.com/news/news-events-pilatus-biosciences 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-events-pilatus-biosciences 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-insights-into-til-therapy-a-new-horizon-in-cancer-treatment 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emerging-insights-into-til-therapy-a-new-horizon-in-cancer-treatment 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/huons-acquires-31-53-stake-in-pangen-biotech-for-10-4-million-to-advance-biopharmaceutical-cdmo-business 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/huons-acquires-31-53-stake-in-pangen-biotech-for-10-4-million-to-advance-biopharmaceutical-cdmo-business 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-s-nhs-data-access-barriers-impede-critical-medical-research-sudlow-review-warns 2024-11-07T23:58:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-s-nhs-data-access-barriers-impede-critical-medical-research-sudlow-review-warns 2024-11-07T23:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/emory-study-estimates-millions-with-depression-could-benefit-from-psychedelic-mushrooms 2024-11-07T23:37:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emory-study-estimates-millions-with-depression-could-benefit-from-psychedelic-mushrooms 2024-11-07T23:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-hiv-combination-antiretroviral-medication-in-black-individuals-contagion-live 2024-11-07T23:31:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-of-hiv-combination-antiretroviral-medication-in-black-individuals-contagion-live 2024-11-07T23:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/vanda-seeks-new-markets-for-hetlioz-amid-generic-competition-sleep-review 2024-11-07T23:26:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vanda-seeks-new-markets-for-hetlioz-amid-generic-competition-sleep-review 2024-11-07T23:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/89bio-inc-sec-10-q-report-tradingview 2024-11-07T23:08:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/89bio-inc-sec-10-q-report-tradingview 2024-11-07T23:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/esperion-therapeutics-inc-sec-10-q-report-tradingview 2024-11-07T23:08:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esperion-therapeutics-inc-sec-10-q-report-tradingview 2024-11-07T23:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-provides-business-and-clinical-update-and-reports-third-quarter 2024-11-07T23:02:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-provides-business-and-clinical-update-and-reports-third-quarter 2024-11-07T23:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/achieve-life-sciences-reports-financial-results-for-third-quarter-2024-and-provides 2024-11-07T22:29:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/achieve-life-sciences-reports-financial-results-for-third-quarter-2024-and-provides 2024-11-07T22:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/alx-oncology-holdings-inc-sec-10-q-report-tradingview 2024-11-07T22:24:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alx-oncology-holdings-inc-sec-10-q-report-tradingview 2024-11-07T22:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-medtech-gains-fda-approval-for-varipulse-pfa-system 2024-11-07T22:14:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-medtech-gains-fda-approval-for-varipulse-pfa-system 2024-11-07T22:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-07T22:13:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longboard-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-07T22:13:21+00:00 weekly 0.7 https://trial.medpath.com/news/ecog-acrin-and-precog-announce-multiple-presentations-at-ash-2024-eurekalert 2024-11-07T22:00:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ecog-acrin-and-precog-announce-multiple-presentations-at-ash-2024-eurekalert 2024-11-07T22:00:38+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-discontinues-work-on-next-gen-exon-skipping-drug-for-duchenne-endpoints-news 2024-11-07T21:53:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-discontinues-work-on-next-gen-exon-skipping-drug-for-duchenne-endpoints-news 2024-11-07T21:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/field-medical-s-fieldforce-pfa-system-receives-fda-breakthrough-designation-for-ventricular-tachycardia-treatment 2024-11-07T21:48:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/field-medical-s-fieldforce-pfa-system-receives-fda-breakthrough-designation-for-ventricular-tachycardia-treatment 2024-11-07T21:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/vistagen-reports-fiscal-year-2025-second-quarter-financial-results-and-corporate-update 2024-11-07T21:35:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vistagen-reports-fiscal-year-2025-second-quarter-financial-results-and-corporate-update 2024-11-07T21:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-discontinues-development-of-duchenne-aso-treatment-vesleteplirsen 2024-11-07T21:33:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-discontinues-development-of-duchenne-aso-treatment-vesleteplirsen 2024-11-07T21:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-reports-third-quarter-2024-financial-results-markets-data 2024-11-07T21:23:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-reports-third-quarter-2024-financial-results-markets-data 2024-11-07T21:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/profound-medical-announces-third-quarter-2024-financial-results-globenewswire 2024-11-07T21:17:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/profound-medical-announces-third-quarter-2024-financial-results-globenewswire 2024-11-07T21:17:51+00:00 weekly 0.7 https://trial.medpath.com/news/rocket-pharmaceuticals-reports-third-quarter-2024-financial-results-and-highlights 2024-11-07T21:16:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rocket-pharmaceuticals-reports-third-quarter-2024-financial-results-and-highlights 2024-11-07T21:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/relmada-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-07T21:16:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relmada-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-07T21:16:12+00:00 weekly 0.7 https://trial.medpath.com/news/iovance-biotherapeutics-reports-financial-results-and-globenewswire 2024-11-07T21:12:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iovance-biotherapeutics-reports-financial-results-and-globenewswire 2024-11-07T21:12:22+00:00 weekly 0.7 https://trial.medpath.com/news/senseonics-holdings-inc-reports-third-quarter-2024-financial-results-stock-titan 2024-11-07T21:12:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senseonics-holdings-inc-reports-third-quarter-2024-financial-results-stock-titan 2024-11-07T21:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/lantern-pharma-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-07T21:12:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantern-pharma-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-07T21:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-reports-third-quarter-2024-financial-results 2024-11-07T21:11:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kura-oncology-reports-third-quarter-2024-financial-results 2024-11-07T21:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/nkarta-reports-third-quarter-2024-financial-results-and-corporate-highlights 2024-11-07T21:11:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nkarta-reports-third-quarter-2024-financial-results-and-corporate-highlights 2024-11-07T21:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-07T21:10:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-07T21:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/bioatla-reports-third-quarter-2024-financial-results-and-highlights-recent-progress 2024-11-07T21:03:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioatla-reports-third-quarter-2024-financial-results-and-highlights-recent-progress 2024-11-07T21:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/nimbus-therapeutics-presents-positive-updated-data-from-phase-1-2-clinical-trial-of-hpk1 2024-11-07T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nimbus-therapeutics-presents-positive-updated-data-from-phase-1-2-clinical-trial-of-hpk1 2024-11-07T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/intravitreal-implant-could-transform-wet-amd-treatment-medpage-today 2024-11-07T20:56:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intravitreal-implant-could-transform-wet-amd-treatment-medpage-today 2024-11-07T20:56:14+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-scraps-a-duchenne-drug-as-gene-therapy-sales-rise-biopharma-dive 2024-11-07T20:50:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-scraps-a-duchenne-drug-as-gene-therapy-sales-rise-biopharma-dive 2024-11-07T20:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/hope-biosciences-stem-cell-therapy-shows-promise-in-small-phase-2-trial 2024-11-07T20:39:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-biosciences-stem-cell-therapy-shows-promise-in-small-phase-2-trial 2024-11-07T20:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-proposes-banning-oral-phenylephrine-in-decongestants-ny1 2024-11-07T20:37:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-proposes-banning-oral-phenylephrine-in-decongestants-ny1 2024-11-07T20:37:27+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-aims-to-enter-glp-1-market-with-different-drug-approach-insidehealthpolicy-com 2024-11-07T20:34:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-aims-to-enter-glp-1-market-with-different-drug-approach-insidehealthpolicy-com 2024-11-07T20:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/late-breaking-clinical-data-and-real-world-evidence-presented-at-hiv-glasgow-as-gilead 2024-11-07T20:30:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/late-breaking-clinical-data-and-real-world-evidence-presented-at-hiv-glasgow-as-gilead 2024-11-07T20:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-clinical-trial-protocol-as-a-pointer-to-the-claimed-crystalline-form-of-a-compound-t-1152-21 2024-11-07T20:10:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-clinical-trial-protocol-as-a-pointer-to-the-claimed-crystalline-form-of-a-compound-t-1152-21 2024-11-07T20:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/new-car-t-cell-trial-launched-through-gates-institute-packages-two-cars-in-one-treatment 2024-11-07T20:10:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-car-t-cell-trial-launched-through-gates-institute-packages-two-cars-in-one-treatment 2024-11-07T20:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/new-dual-target-drug-shows-promise-against-bladder-cancer-jonathan-rosenberg 2024-11-07T20:02:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-dual-target-drug-shows-promise-against-bladder-cancer-jonathan-rosenberg 2024-11-07T20:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-globenewswire 2024-11-07T19:47:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-globenewswire 2024-11-07T19:47:59+00:00 weekly 0.7 https://trial.medpath.com/news/curasight-a-s-publishes-clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients 2024-11-07T19:25:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curasight-a-s-publishes-clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients 2024-11-07T19:25:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-removes-clinical-holds-previously-placed-on-3-of-carsgen-s-oncology-cell-therapies 2024-11-07T19:15:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-removes-clinical-holds-previously-placed-on-3-of-carsgen-s-oncology-cell-therapies 2024-11-07T19:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/the-promise-of-personalized-neurostimulation-in-slowing-alzheimer-progression-neurology-live 2024-11-07T19:14:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-promise-of-personalized-neurostimulation-in-slowing-alzheimer-progression-neurology-live 2024-11-07T19:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-type-c-meeting-to-discuss-paxalisib-pathways-in-glioblastoma 2024-11-07T19:06:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-type-c-meeting-to-discuss-paxalisib-pathways-in-glioblastoma 2024-11-07T19:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-announces-successful-completion-of-end-of-phase-2-globenewswire 2024-11-07T18:56:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/altimmune-announces-successful-completion-of-end-of-phase-2-globenewswire 2024-11-07T18:56:02+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T18:47:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T18:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T18:45:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T18:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/marvel-biosciences-announces-mb204-outperforms-approved-drug-trofinetide-in-a-biospace 2024-11-07T18:40:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marvel-biosciences-announces-mb204-outperforms-approved-drug-trofinetide-in-a-biospace 2024-11-07T18:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/trauma-patients-could-be-enrolled-without-consent-in-study-of-drugs-to-prevent-blood-loss 2024-11-07T18:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trauma-patients-could-be-enrolled-without-consent-in-study-of-drugs-to-prevent-blood-loss 2024-11-07T18:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-pulls-plug-on-duchenne-exon-skipping-drug-pharmaphorum 2024-11-07T18:23:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-pulls-plug-on-duchenne-exon-skipping-drug-pharmaphorum 2024-11-07T18:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T18:18:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T18:18:35+00:00 weekly 0.7